addition compound - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	addition compound	go back to main search page
Accession:	CHEBI:35504	browse the term
Definition:	An addition compound contains two or more simpler compounds that can be packed in a definite ratio into a crystal. The term covers donor-acceptor complexes (adducts) and a variety of lattice compounds.
Synonyms:	related_synonym:	addition compounds

show annotations for term's descendants Sort by:
Rat (707) Mouse (720) Human (722) Chinchilla (0) Bonobo (0) Dog (2) Squirrel (0) Pig (3) Green Monkey (0) Naked Mole-rat (0) All
Genes (707)

Augmentin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of ABCB11 mRNA

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

aldo-keto reductase family 1 member B10

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of AKR1B10 mRNA

NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852

G

caspase 3

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cytochrome c, somatic

increases secretion

Amoxicillin-Potassium Clavulanate Combination results in increased secretion of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 27, subfamily a, polypeptide 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP27A1 mRNA

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP7A1 mRNA

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 8 subfamily B member 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP8B1 mRNA

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

fibroblast growth factor 19

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of FGF19 mRNA

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

glucose-6-phosphate dehydrogenase

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of G6PD mRNA

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

glutamate-cysteine ligase, catalytic subunit

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GCLC mRNA

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GCLM mRNA

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

gamma-glutamyltransferase 1

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GGT1 protein

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

glutamic-oxaloacetic transaminase 1

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of GOT1 protein

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glutamic--pyruvic transaminase

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of GPT protein

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 2

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GPX2 mRNA

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glutathione-disulfide reductase

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GSR mRNA

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

malic enzyme 1

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of ME1 mRNA

NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304

G

nuclear receptor subfamily 0, group B, member 2

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of NR0B2 mRNA

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

solute carrier family 10 member 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of SLC10A1 mRNA

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 51 member A

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of SLC51A mRNA

NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485

G

solute carrier family 7 member 11

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of SLC7A11 mRNA

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

transketolase

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of TKT mRNA

NCBI chr16:5,723,764...5,748,702
Ensembl chr16:5,723,762...5,748,698

G

thioredoxin reductase 1

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of TXNRD1 mRNA

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

carbidopa

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of BAX protein]; Carbidopa inhibits the reaction [Cisplatin results in increased expression of BAX protein]
Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]]

PMID:34560070 PMID:35202708

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Carbidopa inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]

PMID:34560070 PMID:35202708

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]

PMID:34560070 PMID:35202708

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]

PMID:34560070 PMID:35202708

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catechol-O-methyltransferase

increases methylation

COMT protein results in increased methylation of Carbidopa

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

dopa decarboxylase

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of DDC mRNA]
Carbidopa binds to and results in decreased activity of DDC protein

PMID:35151785 PMID:35202708

NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208

G

dynamin 1-like

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]]

NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482

G

fission, mitochondrial 1

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]]

NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377

G

glutamic--pyruvic transaminase

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

interleukin 1 beta

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of IL1B protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased secretion of IL1B protein]; Carbidopa inhibits the reaction [Cisplatin results in increased secretion of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

monoamine oxidase A

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA mRNA]; [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of MAOA protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA mRNA]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]; Carbidopa inhibits the reaction [Cisplatin results in increased expression of MAOA protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]]

PMID:34560070 PMID:35202708

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

mitofusin 1

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]]

NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640

G

mitochondrially encoded ATP synthase membrane subunit 6

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]]

NCBI chr MT:7,919...8,599
NCBI chr MT:7,919...8,599
NCBI chr MT:7,919...8,599
NCBI chr MT:7,919...8,599
NCBI chr MT:7,919...8,599
NCBI chr MT:7,919...8,599
Ensembl chr MT:7,919...8,599

G

mitochondrially encoded cytochrome b

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]]

NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
Ensembl chr MT:14,136...15,278

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]]

NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
Ensembl chr MT:2,740...3,694

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]; Carbidopa inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

synuclein alpha

multiple interactions

[Levodopa co-treated with Carbidopa] inhibits the reaction [Reserpine results in increased expression of SNCA protein]

NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262

G

signal transducer and activator of transcription 3

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

tumor necrosis factor

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of TNF protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased secretion of TNF protein]; Carbidopa inhibits the reaction [Cisplatin results in increased secretion of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tryptophan hydroxylase 1

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of TPH1 mRNA]; [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of TPH1 protein]

NCBI chr 1:97,157,375...97,178,415
Ensembl chr 1:97,157,409...97,178,344

ceftazidime pentahydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 4

increases transport

ABCC4 protein results in increased transport of Ceftazidime

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

dihydrofolate reductase

decreases activity

Ceftazidime results in decreased activity of DHFR protein

NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713

G

heat shock transcription factor 1

decreases activity

Ceftazidime results in decreased activity of HSF1 protein

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

interleukin 10

multiple interactions

Ceftazidime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

cilazapril monohydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

affects response to substance

ACE gene polymorphism affects the susceptibility to Cilazapril

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

adiponectin, C1Q and collagen domain containing

increases expression

Cilazapril results in increased expression of ADIPOQ protein

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

angiotensin II receptor, type 1a

multiple interactions

[Cilazapril co-treated with Losartan] promotes the reaction [Doxorubicin results in increased expression of AGTR1 mRNA]; Cilazapril promotes the reaction [Doxorubicin results in increased expression of AGTR1 mRNA]

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

angiotensin II receptor, type 2

multiple interactions

[Losartan co-treated with Cilazapril] inhibits the reaction [Doxorubicin results in decreased expression of AGTR2 mRNA]; Cilazapril inhibits the reaction [Doxorubicin results in decreased expression of AGTR2 mRNA]

NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057

G

fibroblast growth factor 2

decreases expression

Cilazapril results in decreased expression of FGF2 mRNA; Cilazapril results in decreased expression of FGF2 protein

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

natriuretic peptide A

multiple interactions
affects secretion

[Cilazapril co-treated with Verapamil] affects the secretion of NPPA protein
Cilazapril affects the secretion of NPPA protein

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

renin

increases activity

Cilazapril results in increased activity of REN protein

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

solute carrier family 15 member 1

multiple interactions

Cilazapril inhibits the reaction [SLC15A1 protein results in increased uptake of glycylsarcosine]

NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545

G

solute carrier family 15 member 2

multiple interactions

Cilazapril inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine]

NCBI chr11:64,014,182...64,043,228
Ensembl chr11:64,014,182...64,043,225

G

transforming growth factor, beta 1

multiple interactions

[Losartan co-treated with Cilazapril] inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]; Cilazapril inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

decreases expression

Antimony Potassium Tartrate results in decreased expression of A2M mRNA

NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786

G

ATP binding cassette subfamily C member 1

affects response to substance
decreases response to substance
increases secretion
multiple interactions

ABCC1 protein affects the susceptibility to Antimony Potassium Tartrate
ABCC1 protein results in decreased susceptibility to Antimony Potassium Tartrate
ABCC1 protein results in increased secretion of Antimony Potassium Tartrate
[MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Antimony Potassium Tartrate; Glutathione affects the reaction [ABCC1 protein results in increased secretion of Antimony Potassium Tartrate]; verlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Antimony Potassium Tartrate]; verlukast inhibits the reaction [ABCC1 protein results in increased secretion of Antimony Potassium Tartrate]

PMID:10025956 PMID:10348353 PMID:11278867 PMID:12018890 PMID:12731862

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of ABCC2 mRNA; Antimony Potassium Tartrate results in increased expression of ABCC2 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of ABCC2 mRNA

PMID:11408547 PMID:32076005

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of ABCC3 mRNA

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

acid phosphatase 2, lysosomal

decreases expression

Antimony Potassium Tartrate results in decreased expression of ACP2 mRNA

NCBI chr 3:77,175,022...77,185,180
Ensembl chr 3:77,175,895...77,185,680

G

acyl-CoA synthetase long-chain family member 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of ACSL1 mRNA

NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541

G

adrenomedullin

increases expression

Antimony Potassium Tartrate results in increased expression of ADM mRNA

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

aldo-keto reductase family 1 member B1

decreases expression
increases expression

Antimony Potassium Tartrate results in decreased expression of AKR1B1 mRNA
Antimony Potassium Tartrate results in increased expression of AKR1B1 mRNA

PMID:17547211 PMID:28713220

NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157

G

aldo-keto reductase family 1 member B10

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of AKR1B10 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of AKR1B10 mRNA

PMID:28713220 PMID:32076005

NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852

G

aldo-keto reductase family 1, member C2

increases expression

Antimony Potassium Tartrate results in increased expression of AKR1C2 protein

NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764

G

aldo-keto reductase family 1, member C3

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of AKR1C3 mRNA; Antimony Potassium Tartrate results in increased expression of AKR1C3 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of AKR1C3 mRNA

PMID:28713220 PMID:32076005

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

aldehyde dehydrogenase 3 family, member A2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of ALDH3A2 mRNA

NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281

G

aldehyde dehydrogenase 3 family, member B2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of ALDH3B2 mRNA

NCBI chr 1:201,250,260...201,264,699
Ensembl chr 1:201,253,157...201,264,705

G

aldehyde dehydrogenase 3 family, member B3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of ALDH3B2 mRNA

NCBI chr 1:201,193,832...201,201,666
Ensembl chr 1:201,187,962...201,250,204

G

aldehyde dehydrogenase 6 family, member A1

decreases expression

Antimony Potassium Tartrate results in decreased expression of ALDH6A1 mRNA

NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656

G

aldolase, fructose-bisphosphate A

increases expression

Antimony Potassium Tartrate results in increased expression of ALDOA mRNA

NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182

G

aldolase, fructose-bisphosphate C

increases expression

Antimony Potassium Tartrate results in increased expression of ALDOC mRNA

NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066

G

androgen receptor

increases phosphorylation

Antimony Potassium Tartrate results in increased phosphorylation of AR protein

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

ATPase plasma membrane Ca2+ transporting 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of ATP2B1 mRNA

NCBI chr 7:33,735,595...33,845,226
Ensembl chr 7:33,735,871...33,843,295

G

alpha-2-glycoprotein 1, zinc-binding

decreases expression

Antimony Potassium Tartrate results in decreased expression of AZGP1 mRNA

NCBI chr12:16,930,990...16,939,333
Ensembl chr12:16,931,024...16,939,091

G

BARX homeobox 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of BARX2 mRNA

NCBI chr 8:30,251,132...30,319,105
Ensembl chr 8:30,251,132...30,319,013

G

BCL2 associated X, apoptosis regulator

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

666-15 compound promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of BCL2 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bone morphogenetic protein 6

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP12 mRNA]; Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP2 mRNA]

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

basic transcription factor 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of BTF3 mRNA

NCBI chr 2:29,659,764...29,666,898
Ensembl chr 2:29,659,231...29,666,879

G

BTG anti-proliferation factor 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of BTG2 mRNA

NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628

G

calmodulin-like 5

decreases expression

Antimony Potassium Tartrate results in decreased expression of CALML5 mRNA

NCBI chr17:66,394,433...66,395,352

G

calreticulin

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of CALR mRNA

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

caspase 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased cleavage of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

carbonyl reductase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of CBR1 mRNA

NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393
Ensembl chr11:32,908,950...32,911,393

G

cyclin B2

increases expression

Antimony Potassium Tartrate results in increased expression of CCNB2 mRNA

NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874

G

cyclin D1

multiple interactions

666-15 compound inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein]

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin-dependent kinase inhibitor 1A

increases expression

Antimony Potassium Tartrate results in increased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 2B

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of CDKN2B mRNA

NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050

G

cyclin-dependent kinase inhibitor 3

increases expression

Antimony Potassium Tartrate results in increased expression of CDKN3 mRNA

NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945

G

CCAAT/enhancer binding protein alpha

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of CEBPA mRNA

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

complement factor B

decreases expression

Antimony Potassium Tartrate results in decreased expression of CFB mRNA

NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505

G

CDC28 protein kinase regulatory subunit 2

increases expression

Antimony Potassium Tartrate results in increased expression of CKS2 mRNA

NCBI chr17:13,570,611...13,575,770

G

calmegin

decreases expression

Antimony Potassium Tartrate results in decreased expression of CLGN mRNA

NCBI chr19:24,695,140...24,728,542
Ensembl chr19:24,696,875...24,728,758

G

CLPTM1 regulator of GABA type A receptor forward trafficking

decreases expression

Antimony Potassium Tartrate results in decreased expression of CLPTM1 mRNA

NCBI chr 1:79,289,478...79,321,079
Ensembl chr 1:79,289,477...79,321,092

G

CCHC-type zinc finger, nucleic acid binding protein

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of CNBP mRNA

NCBI chr 4:120,302,768...120,311,694
Ensembl chr 4:120,302,771...120,311,637

G

cAMP responsive element binding protein 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein
[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein; pyrazolanthrone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]

PMID:32920012 PMID:34571074

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of CYP1B1 mRNA

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

DAZ associated protein 1

increases expression

Antimony Potassium Tartrate results in increased expression of DAZAP1 mRNA

NCBI chr 7:9,423,673...9,448,116
Ensembl chr 7:9,424,178...9,538,818

G

decapping mRNA 1A

increases expression

Antimony Potassium Tartrate results in increased expression of DCP1A mRNA

NCBI chr16:5,656,960...5,702,151
Ensembl chr16:5,656,773...5,702,140

G

dehydrogenase/reductase 9

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DHRS9 mRNA

NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241

G

DnaJ heat shock protein family (Hsp40) member B1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DNAJB1 mRNA

NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458

G

DnaJ heat shock protein family (Hsp40) member B4

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of DNAJB4 mRNA

NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089

G

desmocollin 1

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of DSC1 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSC1 mRNA; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSC1 mRNA]

PMID:28713220 PMID:32076005

NCBI chr18:11,499,936...11,556,801
Ensembl chr18:11,502,003...11,528,494

G

desmoglein 1

multiple interactions

2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]

NCBI chr18:11,674,687...11,705,383
Ensembl chr18:11,674,402...11,703,443

G

dystonin

decreases expression

Antimony Potassium Tartrate results in decreased expression of DST protein

NCBI chr 9:36,135,657...36,529,617
Ensembl chr 9:36,135,284...36,529,615

G

dual oxidase 1

multiple interactions
decreases expression

Antimony Potassium Tartrate inhibits the reaction [IL4 protein results in increased expression of DUOX1 mRNA]
Antimony Potassium Tartrate results in decreased expression of DUOX1 mRNA

NCBI chr 3:109,260,526...109,295,588
Ensembl chr 3:109,262,397...109,295,563

G

dual oxidase maturation factor 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of DUOXA1 mRNA

NCBI chr 3:109,249,815...109,260,511
Ensembl chr 3:109,249,923...109,260,499

G

dual specificity phosphatase 1

increases expression

Antimony Potassium Tartrate results in increased expression of DUSP1 mRNA

NCBI chr10:16,680,478...16,683,275

G

dual specificity phosphatase 12

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP12 mRNA]

NCBI chr13:83,122,192...83,131,800
Ensembl chr13:83,122,193...83,131,285

G

dual specificity phosphatase 2

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP2 mRNA]

NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499

G

early growth response 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EGR3 mRNA

NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627

G

ets homologous factor

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EHF mRNA

NCBI chr 3:89,639,845...89,680,061
Ensembl chr 3:89,641,833...89,679,997

G

E74 like ETS transcription factor 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of ELF3 mRNA

NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481

G

Eph receptor A1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EPHA1 protein

NCBI chr 4:71,246,409...71,260,920
Ensembl chr 4:71,246,409...71,260,846

G

Eph receptor A2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EPHA2 protein

NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117

G

epoxide hydrolase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of EPHX1 mRNA

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

coagulation factor V

decreases expression

Antimony Potassium Tartrate results in decreased expression of F5 mRNA

NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317

G

fatty acid binding protein 5

decreases expression

Antimony Potassium Tartrate results in decreased expression of FABP5 mRNA

NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773

G

farnesyl diphosphate farnesyl transferase 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of FDFT1 mRNA

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

farnesyl diphosphate synthase

decreases expression

Antimony Potassium Tartrate results in decreased expression of FDPS mRNA

NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776

G

fibroblast growth factor receptor 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FGFR3 mRNA

NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341

G

filaggrin

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of FLG mRNA
2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]

PMID:28713220 PMID:32076005

NCBI chr 2:178,884,793...178,912,986

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FOS like 1, AP-1 transcription factor subunit

increases expression

Antimony Potassium Tartrate results in increased expression of FOSL1 mRNA

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

forkhead box Q1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FOXQ1 mRNA

NCBI chr17:32,912,744...32,915,377
Ensembl chr17:32,912,744...32,915,377
Ensembl chr17:32,912,744...32,915,377

G

ferritin heavy chain 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of FTH1 mRNA; Antimony Potassium Tartrate results in increased expression of FTH1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of FTH1 mRNA

PMID:28713220 PMID:32076005

NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424

G

ferritin light chain 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of FTL mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of FTL mRNA

PMID:28713220 PMID:32076005

NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725

G

glucose-6-phosphate dehydrogenase

increases expression

Antimony Potassium Tartrate results in increased expression of G6PD mRNA; Antimony Potassium Tartrate results in increased expression of G6PD protein

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

glyceraldehyde-3-phosphate dehydrogenase

increases expression

Antimony Potassium Tartrate results in increased expression of GAPDH mRNA

NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235

G

glutamate-cysteine ligase, catalytic subunit

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of GCLC mRNA; Antimony Potassium Tartrate results in increased expression of GCLC protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GCLC mRNA

PMID:28713220 PMID:32076005

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of GCLM mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GCLM mRNA

PMID:28713220 PMID:32076005

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

glucosaminyl (N-acetyl) transferase 3, mucin type

increases expression

Antimony Potassium Tartrate results in increased expression of GCNT3 mRNA

NCBI chr 8:70,689,173...70,696,476
Ensembl chr 8:70,686,844...70,699,562

G

glial fibrillary acidic protein

multiple interactions

666-15 compound inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA]

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

gamma-glutamyltransferase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GGT1 mRNA

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

growth hormone inducible transmembrane protein

decreases expression

Antimony Potassium Tartrate results in decreased expression of GHITM mRNA

NCBI chr16:12,885,551...12,897,887
Ensembl chr16:12,885,553...12,897,879

G

galactosidase, alpha

increases expression

Antimony Potassium Tartrate results in increased expression of GLA mRNA

NCBI chr X:97,769,227...97,780,646
Ensembl chr X:97,768,996...97,780,664

G

glutaredoxin

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GLRX mRNA

NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680

G

glutathione peroxidase 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GPX2 mRNA

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

grainyhead-like transcription factor 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of GRHL1 mRNA

NCBI chr 6:41,207,325...41,257,516
Ensembl chr 6:41,207,348...41,254,301

G

glutathione S-transferase omega 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GSTO1 mRNA

NCBI chr 1:246,721,089...246,731,228
Ensembl chr 1:246,721,221...246,731,468

G

GTP binding protein 6 (putative)

increases expression

Antimony Potassium Tartrate results in increased expression of GTPBP6 mRNA

NCBI chr12:46,574,913...46,578,873
Ensembl chr12:46,574,435...46,578,873

G

helicase-like transcription factor

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HLTF mRNA

NCBI chr 2:102,549,724...102,609,492
Ensembl chr 2:102,549,724...102,609,327

G

high mobility group AT-hook 1

increases expression

Antimony Potassium Tartrate results in increased expression of HMGA1 mRNA

NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752

G

heme oxygenase 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of HMOX1 mRNA; Antimony Potassium Tartrate results in increased expression of HMOX1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HMOX1 mRNA

PMID:17547211 PMID:28713220 PMID:32076005

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

HOP homeobox

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of HOPX mRNA

NCBI chr14:31,055,912...31,082,909
Ensembl chr14:31,075,148...31,082,909

G

hydroxysteroid (17-beta) dehydrogenase 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of HSD17B2 mRNA

NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202

G

hydroxysteroid (17-beta) dehydrogenase 7

decreases expression

Antimony Potassium Tartrate results in decreased expression of HSD17B7 mRNA

NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017

G

heat shock protein family A (Hsp70) member 1A

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HSPA1A mRNA

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

heat shock protein family A (Hsp70) member 8

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HSPA8 mRNA

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

heat shock protein family B (small) member 8

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HSPB8 mRNA

NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185

G

HIV-1 Tat interactive protein 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HTATIP2 mRNA

NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629

G

inhibitor of DNA binding 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of ID1 mRNA

NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419

G

immediate early response 2

increases expression

Antimony Potassium Tartrate results in increased expression of IER2 mRNA

NCBI chr19:23,494,551...23,496,075
Ensembl chr19:23,494,184...23,499,211

G

interferon-related developmental regulator 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of IFRD1 mRNA

NCBI chr 6:57,269,395...57,317,833
Ensembl chr 6:57,269,384...57,288,990

G

IKAROS family zinc finger 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of IKZF2 mRNA

NCBI chr 9:71,046,038...71,191,296
Ensembl chr 9:71,042,440...71,190,867

G

interleukin 1 receptor antagonist

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of IL1RN mRNA

NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445

G

interleukin 4

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [IL4 protein results in increased expression of DUOX1 mRNA]

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

inhibitor of growth family, member 3

increases expression

Antimony Potassium Tartrate results in increased expression of ING3 mRNA

NCBI chr 4:50,477,954...50,505,168
Ensembl chr 4:50,477,962...50,503,715

G

integrin subunit beta 3 binding protein

increases expression

Antimony Potassium Tartrate results in increased expression of ITGB3BP mRNA

NCBI chr 5:114,460,217...114,525,538
Ensembl chr 5:114,460,221...114,525,704

G

inter-alpha trypsin inhibitor, heavy chain 3

decreases expression

Antimony Potassium Tartrate results in decreased expression of ITIH3 mRNA

NCBI chr16:6,101,922...6,117,154
Ensembl chr16:6,101,930...6,116,924

G

involucrin

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of IVL mRNA; Antimony Potassium Tartrate results in decreased expression of IVL protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of IVL mRNA

PMID:28713220 PMID:32076005

NCBI chr 2:178,146,694...178,160,807
Ensembl chr 2:178,147,061...178,149,100

G

KLF transcription factor 5

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KLF5 mRNA

NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445

G

KLF transcription factor 6

increases expression

Antimony Potassium Tartrate results in increased expression of KLF6 mRNA

NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570

G

kallikrein 1-related peptidase C10

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of KLK3 mRNA; Antimony Potassium Tartrate results in increased expression of KLK3 protein
bicalutamide inhibits the reaction [Antimony Potassium Tartrate results in increased expression of KLK3 mRNA]

NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052

G

keratin 1

multiple interactions

2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]

NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844

G

keratin 10

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of KRT10 mRNA; Antimony Potassium Tartrate results in decreased expression of KRT10 protein
2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]

PMID:28713220 PMID:32076005

NCBI chr10:84,338,695...84,343,279
Ensembl chr10:84,338,706...84,343,701

G

keratinocyte differentiation associated protein

decreases expression

Antimony Potassium Tartrate results in decreased expression of KRTDAP mRNA

NCBI chr 1:86,038,296...86,041,594
Ensembl chr 1:86,038,437...86,041,455

G

lipase A, lysosomal acid type

decreases expression

Antimony Potassium Tartrate results in decreased expression of LIPA mRNA

NCBI chr 1:232,024,351...232,057,735
Ensembl chr 1:232,024,356...232,057,633

G

loricrin cornified envelope precursor protein

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of LORICRIN mRNA

NCBI chr 2:177,558,062...177,560,960
Ensembl chr 2:177,558,252...177,559,807

G

leucine-rich repeats and immunoglobulin-like domains 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of LRIG1 mRNA

NCBI chr 4:127,130,899...127,230,956
Ensembl chr 4:127,130,898...127,231,513

G

lanosterol synthase

decreases expression

Antimony Potassium Tartrate results in decreased expression of LSS mRNA

NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762

G

MAF bZIP transcription factor F

increases expression

Antimony Potassium Tartrate results in increased expression of MAFF mRNA

NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851

G

mannosidase, alpha, class 1A, member 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of MAN1A2 mRNA

NCBI chr 2:187,947,484...188,096,332
Ensembl chr 2:187,951,617...188,096,332

G

monoamine oxidase A

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of MAOA mRNA

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

mitogen activated protein kinase kinase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of MAP2K1 mRNA

NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of MAPK1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased phosphorylation of MAPK1 protein

PMID:32076005 PMID:32920012 PMID:34571074

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of MAPK3 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased phosphorylation of MAPK3 protein

PMID:32076005 PMID:32920012 PMID:34571074

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

minichromosome maintenance complex component 2

increases expression

Antimony Potassium Tartrate results in increased expression of MCM2 mRNA

NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847

G

malic enzyme 1

increases expression

Antimony Potassium Tartrate results in increased expression of ME1 mRNA

NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304

G

alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase

decreases expression

Antimony Potassium Tartrate results in decreased expression of MGAT2 mRNA

NCBI chr 6:87,656,360...87,658,849
Ensembl chr 6:87,656,349...87,658,177

G

microsomal glutathione S-transferase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of MGST1 mRNA

NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892

G

metallothionein 1, pseudogene 3

increases expression

Antimony Potassium Tartrate results in increased expression of MT1E mRNA

NCBI chr17:74,786,652...74,787,040
Ensembl chr17:74,786,654...74,787,135

G

metallothionein 2A

increases expression

Antimony Potassium Tartrate results in increased expression of MT2A mRNA

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

MYCN proto-oncogene, bHLH transcription factor

multiple interactions
decreases response to substance

[MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Antimony Potassium Tartrate
MYCN protein results in decreased susceptibility to Antimony Potassium Tartrate

NCBI chr 6:35,717,764...35,723,590
Ensembl chr 6:35,717,764...35,723,590

G

NDRG family member 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of NDRG2 mRNA

NCBI chr15:24,600,981...24,609,621
Ensembl chr15:24,600,982...24,609,626

G

nuclear factor kappa B subunit 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of NFKB2 mRNA

NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213

G

NFKB inhibitor alpha

decreases expression

Antimony Potassium Tartrate results in decreased expression of NFKBIA mRNA

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NK3 homeobox 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of NKX3-1 mRNA; Antimony Potassium Tartrate results in increased expression of NKX3-1 protein
bicalutamide inhibits the reaction [Antimony Potassium Tartrate results in increased expression of NKX3-1 mRNA]

NCBI chr15:44,473,851...44,476,443
Ensembl chr15:44,473,851...44,476,441

G

nitric oxide synthase 2

multiple interactions

666-15 compound inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 mRNA; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NAD(P)H quinone dehydrogenase 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of NQO1 mRNA; Antimony Potassium Tartrate results in increased expression of NQO1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of NQO1 mRNA

PMID:28713220 PMID:32076005

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

N-ribosyldihydronicotinamide:quinone dehydrogenase 2

increases expression

Antimony Potassium Tartrate results in increased expression of NQO2 mRNA

NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320

G

nuclear receptor subfamily 0, group B, member 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of NR0B2 mRNA

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

OS9, endoplasmic reticulum lectin

decreases expression

Antimony Potassium Tartrate results in decreased expression of OS9 mRNA

NCBI chr 7:62,915,498...62,957,591
Ensembl chr 7:62,915,515...62,943,745

G

oncostatin M

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]

NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313

G

PBX homeobox 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PBX1 mRNA

NCBI chr13:80,278,766...80,588,563
Ensembl chr13:80,278,770...80,588,594

G

proliferating cell nuclear antigen

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of PCNA protein

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

protein disulfide isomerase family A, member 4

decreases expression

Antimony Potassium Tartrate results in decreased expression of PDIA4 mRNA

NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107

G

progastricsin

decreases expression

Antimony Potassium Tartrate results in decreased expression of PGC mRNA

NCBI chr 9:13,257,462...13,265,682
Ensembl chr 9:13,257,462...13,265,682

G

phosphogluconate dehydrogenase

increases expression

Antimony Potassium Tartrate results in increased expression of PGD protein

NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778

G

phosphoglucomutase 1

increases expression

Antimony Potassium Tartrate results in increased expression of PGM1 mRNA

NCBI chr 5:114,595,298...114,654,728
Ensembl chr 5:114,595,293...114,654,728

G

phosphoglucomutase 3

increases expression

Antimony Potassium Tartrate results in increased expression of PGM3 mRNA

NCBI chr 8:87,518,317...87,536,021
Ensembl chr 8:87,517,701...87,536,022

G

phosphoinositide-3-kinase regulatory subunit 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PIK3R1 mRNA

NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631

G

phosphoinositide-3-kinase regulatory subunit 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PIK3R2 mRNA

NCBI chr16:18,665,517...18,674,067
Ensembl chr16:18,665,457...18,674,065

G

pirin

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of PIR mRNA

NCBI chr X:30,108,536...30,219,269
Ensembl chr X:30,108,538...30,219,218

G

paired-like homeodomain 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PITX1 mRNA

NCBI chr17:8,794,134...8,800,292
Ensembl chr17:8,794,134...8,800,291

G

PML nuclear body scaffold

affects localization
multiple interactions
increases degradation

Antimony Potassium Tartrate affects the localization of PML protein
Antimony Potassium Tartrate promotes the reaction [SUMO1 protein binds to PML protein]
Antimony Potassium Tartrate results in increased degradation of PML protein mutant form

NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971

G

peptidylprolyl isomerase H

increases expression

Antimony Potassium Tartrate results in increased expression of PPIH mRNA

NCBI chr 5:132,906,324...132,924,341
Ensembl chr 5:132,906,328...132,924,267

G

peroxiredoxin 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of PRDX1 mRNA

NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856

G

phosphoserine phosphatase

decreases expression

Antimony Potassium Tartrate results in decreased expression of PSPH mRNA

NCBI chr12:26,882,524...26,905,084
Ensembl chr12:26,883,133...26,905,074

G

PTTG1 regulator of sister chromatid separation, securin

increases expression

Antimony Potassium Tartrate results in increased expression of PTTG1 mRNA

NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837

G

retinoic acid receptor, alpha

increases degradation

Antimony Potassium Tartrate results in increased degradation of RARA protein mutant form

NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142

G

RNA binding protein, mRNA processing factor

increases expression

Antimony Potassium Tartrate results in increased expression of RBPMS mRNA

NCBI chr16:58,239,370...58,395,424
Ensembl chr16:58,239,474...58,395,426

G

replication factor C subunit 2

increases expression

Antimony Potassium Tartrate results in increased expression of RFC2 mRNA

NCBI chr12:22,120,449...22,133,576
Ensembl chr12:22,120,010...22,133,557

G

ribonuclease H2, subunit A

increases expression

Antimony Potassium Tartrate results in increased expression of RNASEH2A mRNA

NCBI chr19:23,186,325...23,196,045
Ensembl chr19:23,186,383...23,196,041

G

ribonuclease/angiogenin inhibitor 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of RNH1 protein

NCBI chr 1:196,269,293...196,281,763
Ensembl chr 1:196,269,293...196,281,910

G

repetin

decreases expression

Antimony Potassium Tartrate results in decreased expression of RPTN mRNA

NCBI chr 2:179,061,768...179,066,056
Ensembl chr 2:179,060,017...179,065,910

G

ryanodine receptor 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of RYR1 mRNA

NCBI chr 1:84,292,578...84,423,824
Ensembl chr 1:84,292,578...84,423,812

G

S100 calcium binding protein A2

decreases expression

Antimony Potassium Tartrate results in decreased expression of S100A2 mRNA

NCBI chr 2:176,077,081...176,078,325

G

S100 calcium binding protein A8

decreases expression

Antimony Potassium Tartrate results in decreased expression of S100A8 mRNA; Antimony Potassium Tartrate results in decreased expression of S100A8 protein

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

S100 calcium binding protein A9

decreases expression

Antimony Potassium Tartrate results in decreased expression of S100A9 mRNA; Antimony Potassium Tartrate results in decreased expression of S100A9 protein

NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230

G

stearoyl-CoA desaturase

decreases expression

Antimony Potassium Tartrate results in decreased expression of SCD mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

selenophosphate synthetase 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of SEPHS2 mRNA

NCBI chr 1:181,893,146...181,895,464
Ensembl chr 1:181,892,599...181,895,497

G

serpin family B member 1A

decreases expression

Antimony Potassium Tartrate results in decreased expression of SERPINB1 mRNA

NCBI chr17:31,590,695...31,599,102
Ensembl chr17:31,590,677...31,599,102

G

serpin family C member 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of SERPINC1 mRNA

NCBI chr13:73,257,208...73,271,476
Ensembl chr13:73,257,179...73,284,293

G

serpin family E member 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

salt-inducible kinase 1

increases expression

Antimony Potassium Tartrate results in increased expression of SIK1 mRNA

NCBI chr20:9,949,407...9,959,036
Ensembl chr20:9,947,396...9,958,991

G

solute carrier family 2 member 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SLC2A3 mRNA

NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472

G

small nuclear ribonucleoprotein polypeptide A

increases expression

Antimony Potassium Tartrate results in increased expression of SNRPA mRNA

NCBI chr 1:82,481,770...82,490,540
Ensembl chr 1:82,481,770...82,490,538

G

superoxide dismutase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SOD1 mRNA

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

small proline-rich protein 1A

decreases expression

Antimony Potassium Tartrate results in decreased expression of SPRR1A mRNA; Antimony Potassium Tartrate results in decreased expression of SPRR1A protein

NCBI chr 2:178,055,096...178,057,012
Ensembl chr 2:178,055,096...178,057,063

G

small proline-rich protein 1B

decreases expression

Antimony Potassium Tartrate results in decreased expression of SPRR1B mRNA; Antimony Potassium Tartrate results in decreased expression of SPRR1B protein

NCBI chr 2:178,008,844...178,010,742
Ensembl chr 2:178,009,130...178,009,567

G

small proline-rich protein 3

decreases expression

Antimony Potassium Tartrate results in decreased expression of SPRR3 mRNA; Antimony Potassium Tartrate results in decreased expression of SPRR3 protein

NCBI chr 2:178,027,743...178,028,501
Ensembl chr 2:178,027,425...178,029,891

G

squalene epoxidase

decreases expression

Antimony Potassium Tartrate results in decreased expression of SQLE mRNA

NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618

G

sequestosome 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SQSTM1 mRNA

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

serine and arginine rich splicing factor 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of SRSF1 mRNA

NCBI chr10:72,838,926...72,859,066
Ensembl chr10:72,839,274...72,845,336

G

serine and arginine rich splicing factor 5

decreases expression

Antimony Potassium Tartrate results in decreased expression of SRSF5 mRNA

NCBI chr 6:100,605,165...100,610,192
Ensembl chr 6:100,605,456...100,610,177

G

sulfiredoxin 1

increases expression

Antimony Potassium Tartrate results in increased expression of SRXN1 mRNA

NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448

G

ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 4

decreases expression

Antimony Potassium Tartrate results in decreased expression of ST6GALNAC4 mRNA

NCBI chr 3:15,872,230...15,885,250
Ensembl chr 3:15,872,532...15,885,243

G

signal transducer and activator of transcription 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of STAT1 mRNA

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

sulfotransferase family 1C member 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of SULT1C3 mRNA

NCBI chr 9:7,221,580...7,266,991
Ensembl chr 9:7,221,578...7,267,030

G

sulfotransferase family 1E member 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of SULT1E1 mRNA

NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275

G

sulfotransferase family 2B member 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of SULT2B1 mRNA

NCBI chr 1:96,200,155...96,261,295
Ensembl chr 1:96,200,156...96,261,295

G

small ubiquitin-like modifier 1

affects localization
multiple interactions

Antimony Potassium Tartrate affects the localization of SUMO1 protein
Antimony Potassium Tartrate promotes the reaction [SUMO1 protein binds to PML protein]

NCBI chr 9:61,078,790...61,108,697
Ensembl chr 9:61,077,435...61,108,761

G

TAR DNA binding protein

decreases expression

Antimony Potassium Tartrate results in decreased expression of TARDBP mRNA

NCBI chr 5:159,050,518...159,062,218
Ensembl chr 5:159,051,799...159,062,055

G

transglutaminase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of TGM1 mRNA

NCBI chr15:29,191,039...29,206,000
Ensembl chr15:29,191,041...29,204,523

G

TNF alpha induced protein 3

increases expression

Antimony Potassium Tartrate results in increased expression of TNFAIP3 mRNA

NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282

G

TNF superfamily member 10

decreases expression

Antimony Potassium Tartrate results in decreased expression of TNFSF10 mRNA

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

transducer of ErbB-2.1

decreases expression

Antimony Potassium Tartrate results in decreased expression of TOB1 mRNA

NCBI chr10:79,163,093...79,165,131
Ensembl chr10:79,160,154...79,165,215

G

tumor protein p63

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of TP63 mRNA

NCBI chr11:74,838,858...75,049,764
Ensembl chr11:74,838,859...75,049,398

G

triosephosphate isomerase 1

increases expression

Antimony Potassium Tartrate results in increased expression of TPI1 mRNA

NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541

G

TSC22 domain family, member 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of TSC22D3 mRNA

NCBI chr X:104,217,898...104,277,886
Ensembl chr X:104,217,925...104,276,861

G

tetraspanin 7

decreases expression

Antimony Potassium Tartrate results in decreased expression of TSPAN7 mRNA

NCBI chr X:12,208,783...12,306,092
Ensembl chr X:12,208,783...12,306,131

G

tuftelin 1

increases expression

Antimony Potassium Tartrate results in increased expression of TUFT1 mRNA

NCBI chr 2:182,259,457...182,306,296
Ensembl chr 2:182,260,398...182,306,192

G

thioredoxin 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of TXN mRNA

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

G

thioredoxin reductase 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of TXNRD1 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of TXNRD1 mRNA

PMID:17547211 PMID:28713220 PMID:32076005

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

G

thymidylate synthetase

increases expression

Antimony Potassium Tartrate results in increased expression of TYMS mRNA

NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536

G

ubiquitin-conjugating enzyme E2C

increases expression

Antimony Potassium Tartrate results in increased expression of UBE2C mRNA

NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339

G

UDP glucuronosyltransferase family 1 member A6

multiple interactions
increases expression

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of UGT1A6 mRNA
Antimony Potassium Tartrate results in increased expression of UGT1A6 mRNA

PMID:28713220 PMID:32076005

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

ZW10 interacting kinetochore protein

increases expression

Antimony Potassium Tartrate results in increased expression of ZWINT mRNA

NCBI chr20:15,938,157...15,953,997
Ensembl chr20:15,938,157...15,953,957

enalaprilat dihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

multiple interactions

Enalaprilat inhibits the reaction [Glucose results in increased expression of ACE protein]

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

adrenoceptor beta 1

affects expression

Enalaprilat affects the expression of ADRB1 protein

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

affects expression

Enalaprilat affects the expression of ADRB2 protein

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

angiotensinogen

decreases expression
multiple interactions

Enalaprilat results in decreased expression of AGT protein modified form
Enalaprilat inhibits the reaction [Glucose results in increased expression of AGT protein]

PMID:16452552 PMID:21795644

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

angiotensin II receptor, type 1a

multiple interactions

Enalaprilat inhibits the reaction [Glucose results in increased expression of AGTR1 protein]

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

BCL2, apoptosis regulator

increases expression

Enalaprilat results in increased expression of BCL2 mRNA

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bradykinin receptor B1

multiple interactions
increases activity

bradykinin, Lys-Leu(8)-desArg(9)- inhibits the reaction [Enalaprilat results in increased activity of BDKRB1 protein]; Zinc affects the reaction [Enalaprilat results in increased activity of BDKRB1 protein]

NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747

G

endothelin 1

decreases secretion

Enalaprilat results in decreased secretion of EDN1 protein

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

fibronectin 1

decreases expression
multiple interactions

Enalaprilat results in decreased expression of FN1 mRNA; Enalaprilat results in decreased expression of FN1 protein
Enalaprilat inhibits the reaction [Glucose results in increased expression of FN1 mRNA]

PMID:14520012 PMID:21795644

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

glutamate dehydrogenase 1

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in decreased expression of GLUD1 mRNA]; Enalaprilat inhibits the reaction [Dexamethasone results in decreased expression of GLUD2 mRNA]

NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957

G

glutamate metabotropic receptor 1

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of GRM1 mRNA]

NCBI chr 1:5,058,285...5,453,170
Ensembl chr 1:5,058,292...5,453,170

G

high mobility group box 1

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of HMGB1 mRNA]; Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of HMGB1 protein]

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

insulin 2

multiple interactions

Enalaprilat inhibits the reaction [Glucose results in decreased secretion of INS protein]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

peroxisome proliferator-activated receptor delta

multiple interactions

[Enalaprilat co-treated with Daunorubicin] results in increased expression of PPARD mRNA

NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968

G

renin

increases expression

Enalaprilat results in increased expression of REN mRNA

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

serpin family E member 1

decreases expression

Enalaprilat results in decreased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

solute carrier family 22 member 8

multiple interactions
increases uptake

verlukast inhibits the reaction [SLC22A8 protein results in increased uptake of Enalaprilat]

NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450

G

transforming growth factor, beta 1

decreases expression

Enalaprilat results in decreased expression of TGFB1 mRNA; Enalaprilat results in decreased expression of TGFB1 protein

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

toll-like receptor 4

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of TLR4 mRNA]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

decreases expression

Enalaprilat results in decreased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

gadodiamide hydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adiponectin, C1Q and collagen domain containing

decreases expression

gadodiamide results in decreased expression of ADIPOQ mRNA; gadodiamide results in decreased expression of ADIPOQ protein

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

AKT serine/threonine kinase 1

increases phosphorylation
multiple interactions

gadodiamide results in increased phosphorylation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aldehyde dehydrogenase 1 family, member A1

increases expression

gadodiamide results in increased expression of ALDH1A1 mRNA

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

ankyrin repeat domain 22

increases expression

gadodiamide results in increased expression of ANKRD22 mRNA

NCBI chr 1:231,639,035...231,670,537
Ensembl chr 1:231,639,314...231,670,381

G

ATM serine/threonine kinase

increases expression

gadodiamide results in increased expression of ATM mRNA

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

ATPase phospholipid transporting 8B1

increases expression

gadodiamide results in increased expression of ATP8B1 mRNA

NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396

G

C-C motif chemokine ligand 2

increases expression
increases secretion

gadodiamide results in increased expression of CCL2 mRNA
gadodiamide results in increased expression of CCL2 mRNA; gadodiamide results in increased expression of CCL2 protein
gadodiamide results in increased secretion of CCL2 protein

PMID:20938346 PMID:20959327

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 4

increases expression

gadodiamide results in increased expression of CCL4 protein

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 7

increases expression

gadodiamide results in increased expression of CCL7 protein

NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303

G

centrosomal protein 15

increases expression

gadodiamide results in increased expression of CEP15 mRNA

NCBI chr15:12,815,159...12,835,115
Ensembl chr15:12,818,385...12,833,838

G

C-X-C motif chemokine ligand 10

increases expression
increases secretion

gadodiamide results in increased expression of CXCL10 mRNA
gadodiamide results in increased expression of CXCL10 protein
gadodiamide results in increased secretion of CXCL10 protein

PMID:20938346 PMID:20959327

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 11

increases secretion
increases expression

gadodiamide results in increased secretion of CXCL11 protein
gadodiamide results in increased expression of CXCL11 mRNA

NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271

G

C-X-C motif chemokine ligand 12

increases expression

gadodiamide results in increased expression of CXCL12 mRNA

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine ligand 9

increases expression

gadodiamide results in increased expression of CXCL9 mRNA

NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435

G

fatty acid binding protein 4

decreases expression

gadodiamide results in decreased expression of FABP4 mRNA; gadodiamide results in decreased expression of FABP4 protein

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

indoleamine 2,3-dioxygenase 1

increases expression

gadodiamide results in increased expression of IDO1 mRNA

NCBI chr16:67,430,654...67,442,726
Ensembl chr16:67,430,578...67,442,730

G

interferon-induced protein 44-like

increases expression

gadodiamide results in increased expression of IFI44L mRNA

NCBI chr 2:240,668,742...240,706,425
Ensembl chr 2:240,668,713...240,706,359

G

interferon-induced protein with tetratricopeptide repeats 3

increases expression

gadodiamide results in increased expression of IFIT3 mRNA

NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307

G

interferon gamma

increases expression

gadodiamide results in increased expression of IFNG mRNA; gadodiamide results in increased expression of IFNG protein

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 13

increases expression

gadodiamide results in increased expression of IL13 mRNA; gadodiamide results in increased expression of IL13 protein

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 1 alpha

increases expression

gadodiamide results in increased expression of IL1A protein

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 4

increases expression
affects expression

gadodiamide results in increased expression of IL4 protein
gadodiamide affects the expression of IL4 mRNA

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 4 induced 1

increases expression

gadodiamide results in increased expression of IL4I1 mRNA

NCBI chr 1:95,299,457...95,324,564
Ensembl chr 1:95,295,601...95,324,562

G

interleukin 6

affects expression
increases expression

gadodiamide affects the expression of IL6 protein
gadodiamide results in increased expression of IL6 mRNA

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

KIT ligand

increases expression

gadodiamide results in increased expression of KITLG protein

NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 1

multiple interactions
increases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased expression of MMP1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased expression of MMP1 protein]
gadodiamide results in increased expression of MMP1 mRNA; gadodiamide results in increased expression of MMP1 protein

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

nitric oxide synthase 2

increases expression

gadodiamide results in increased expression of NOS2 protein

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

neurexophilin and PC-esterase domain family, member 3

increases expression

gadodiamide results in increased expression of NXPE3 mRNA

NCBI chr11:44,726,905...44,777,694
Ensembl chr11:44,727,069...44,777,694

G

peroxisome proliferator-activated receptor gamma

decreases expression

gadodiamide results in decreased expression of PPARG mRNA; gadodiamide results in decreased expression of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

RELA proto-oncogene, NF-kB subunit

increases localization

gadodiamide results in increased localization of RELA protein

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ras homolog family member Q

increases expression

gadodiamide results in increased expression of RHOQ mRNA

NCBI chr 6:7,613,632...7,652,047

G

Ras-like without CAAX 1

increases expression

gadodiamide results in increased expression of RIT1 mRNA

NCBI chr 2:174,180,742...174,195,455
Ensembl chr 2:174,180,848...174,195,455

G

ring finger protein 125

increases expression

gadodiamide results in increased expression of RNF125 mRNA

NCBI chr18:12,254,066...12,275,719
Ensembl chr18:12,253,852...12,275,983

G

radical S-adenosyl methionine domain containing 2

increases expression

gadodiamide results in increased expression of RSAD2 mRNA

NCBI chr 6:43,046,514...43,059,737
Ensembl chr 6:43,047,658...43,059,699

G

solute carrier family 39 member 10

increases expression

gadodiamide results in increased expression of SLC39A10 mRNA

NCBI chr 9:54,836,841...54,960,325
Ensembl chr 9:54,876,141...54,960,325

G

sialophorin

increases expression

gadodiamide results in increased expression of SPN mRNA

NCBI chr 1:181,746,937...181,759,564
Ensembl chr 1:181,746,429...181,759,628

G

secreted phosphoprotein 1

increases expression

gadodiamide results in increased expression of SPP1 protein

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

transforming growth factor, beta 1

increases expression

gadodiamide results in increased expression of TGFB1 mRNA; gadodiamide results in increased expression of TGFB1 protein

PMID:19404939 PMID:20938346

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

TIMP metallopeptidase inhibitor 1

increases expression
multiple interactions

gadodiamide results in increased expression of TIMP1 mRNA; gadodiamide results in increased expression of TIMP1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [gadodiamide results in increased expression of TIMP1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased expression of TIMP1 protein]

PMID:19561517 PMID:20938346

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

ubiquitin D

increases expression

gadodiamide results in increased expression of UBD mRNA

NCBI chr20:1,385,487...1,387,438
Ensembl chr20:1,385,864...1,408,639
Ensembl chr20:1,385,864...1,408,639

G

vascular endothelial growth factor A

increases expression

gadodiamide results in increased expression of VEGFA mRNA; gadodiamide results in increased expression of VEGFA protein

PMID:19404939 PMID:20938346

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

WD repeat domain 5

increases expression

gadodiamide results in increased expression of WDR5 mRNA

NCBI chr 3:10,836,964...10,856,682
Ensembl chr 3:10,837,025...10,856,671

G

X-linked inhibitor of apoptosis

increases expression

gadodiamide results in increased expression of XIAP mRNA

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

G

zinc finger protein 652

increases expression

gadodiamide results in increased expression of ZNF652 mRNA

NCBI chr10:80,626,555...80,706,397
Ensembl chr10:80,649,400...80,698,674

lisinopril dihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

decreases activity

Lisinopril analog results in decreased activity of ACE protein

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

angiotensin converting enzyme 2

increases expression
increases activity
multiple interactions

Lisinopril results in increased expression of ACE2 mRNA
Lisinopril results in increased activity of ACE2 protein
ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]

PMID:15897343 PMID:16221218 PMID:27649628

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

acetylcholinesterase

multiple interactions

2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]
Lisinopril inhibits the reaction [Sodium Fluoride results in decreased activity of ACHE protein]

PMID:23060470 PMID:31710167

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

angiotensinogen

decreases expression
increases expression
affects response to substance
increases secretion
decreases secretion
multiple interactions
affects metabolic processing

Lisinopril results in decreased expression of AGT protein
Lisinopril results in increased expression of AGT mRNA
AGT gene alternative form affects the susceptibility to Lisinopril
Lisinopril results in increased secretion of AGT protein alternative form
Lisinopril results in decreased secretion of AGT protein
[Lisinopril co-treated with Losartan] results in increased expression of AGT mRNA
Lisinopril affects the metabolism of AGT protein
[[Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein
[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7); [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein; ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]; Thiorphan inhibits the reaction [[Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7)]

PMID:8393685 PMID:8915971 PMID:15897343 PMID:16221218 PMID:16685205 More...

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

BCL2, apoptosis regulator

decreases expression

Lisinopril results in decreased expression of BCL2

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

CD2-associated protein

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in increased expression of CD2AP protein]

NCBI chr 9:18,086,744...18,182,744
Ensembl chr 9:18,086,984...18,182,199

G

endothelin 1

decreases secretion

Lisinopril results in decreased secretion of EDN1 protein

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

growth hormone 1

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

hepatitis A virus cellular receptor 1

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein]

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

heparanase

multiple interactions

[Spironolactone co-treated with Lisinopril] inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]

NCBI chr14:8,896,593...8,937,011
Ensembl chr14:8,896,593...8,937,010

G

insulin-like growth factor binding protein 1

increases expression

Lisinopril results in increased expression of IGFBP1 protein

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

matrix metallopeptidase 2

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

myeloperoxidase

multiple interactions

2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

nitric oxide synthase 2

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NPHS2 stomatin family member, podocin

multiple interactions

Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 mRNA]; Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 protein]

NCBI chr13:68,448,720...68,461,312
Ensembl chr13:68,448,926...68,461,313

G

natriuretic peptide A

decreases expression

Lisinopril results in decreased expression of NPPA protein

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

renin

increases expression
multiple interactions

Lisinopril results in increased expression of REN protein
Lisinopril results in increased expression of REN mRNA
[Lisinopril co-treated with Losartan] results in increased expression of REN mRNA

PMID:2550029 PMID:8915971 PMID:16221218

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

RT1 class Ib, locus M3, gene 1

affects expression

Lisinopril affects the expression of HLA-G mRNA

NCBI chr20:1,323,976...1,328,126
Ensembl chr20:1,287,521...1,328,117

G

sperm microtubule inner protein 11

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in decreased phosphorylation of NPHS1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NPHS1 protein]

PMID:16636307 PMID:19293598

NCBI chr 7:129,720,950...129,742,485
Ensembl chr 7:129,720,950...129,742,485

G

TIMP metallopeptidase inhibitor 1

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

vascular endothelial growth factor A

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of VEGFA protein]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

mosapride citrate dihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

anoctamin 1

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of ANO1 mRNA]; mosapride inhibits the reaction [Loperamide results in decreased expression of ANO1 protein]

NCBI chr 1:199,751,439...199,900,099
Ensembl chr 1:199,751,439...199,900,069

G

5-hydroxytryptamine receptor 4

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of HTR4 mRNA]

NCBI chr18:55,765,981...55,949,921
Ensembl chr18:55,766,725...55,949,321

G

myosin light chain kinase

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of MYLK mRNA]

NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261

G

nitric oxide synthase 1

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of NOS1 protein]

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

ryanodine receptor 3

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of RYR3 mRNA]

NCBI chr 3:99,431,755...99,979,125
Ensembl chr 3:99,432,505...99,704,961

G

solute carrier family 22 member 2

multiple interactions

mosapride inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

potassium citrate monohydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

neurofilament heavy chain

affects expression

Potassium Citrate affects the expression of NEFH mRNA

NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351

sodium acetate trihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA oxidase 1

increases expression

Sodium Acetate results in increased expression of ACOX1 mRNA

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

acyl-CoA synthetase short-chain family member 1

increases expression

Sodium Acetate results in increased expression of ACSS1 mRNA

NCBI chr 3:139,450,383...139,500,325
Ensembl chr 3:139,450,383...139,500,325

G

acyl-CoA synthetase short-chain family member 2

increases expression

Sodium Acetate results in increased expression of ACSS2 mRNA

NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675

G

adenosine deaminase

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased activity of ADA protein]

NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088

G

apolipoprotein B

multiple interactions

[Sodium Acetate co-treated with acetic anhydride] results in increased acetylation of APOB protein

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

caspase 3

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in increased cleavage of CASP7 protein]

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

catalase

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in decreased expression of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
Sodium Acetate promotes the reaction [biochanin A results in increased expression of CYP1A1 mRNA]; Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions

Sodium Acetate promotes the reaction [biochanin A results in increased expression of CYP1B1 mRNA]; Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

gamma-glutamyltransferase 1

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased activity of GGT1 protein]

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

interferon gamma

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IFNG mRNA]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IKBKB mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IKBKB protein]

NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250

G

interleukin 2

multiple interactions

Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 protein]

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 6

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased expression of INS1 protein]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

karyopherin subunit beta 1

multiple interactions

Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]

NCBI chr10:82,145,662...82,174,437
Ensembl chr10:82,145,420...82,174,605

G

MYD88, innate immune signal transduction adaptor

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of MYD88 mRNA]

NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415

G

N-acetyltransferase 2

increases expression

Sodium Acetate results in increased expression of NAT2 mRNA

NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520

G

nuclear factor of activated T-cells 2

multiple interactions

Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of NFATC2 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of NFATC2 protein]

NCBI chr 3:157,195,970...157,328,640
Ensembl chr 3:157,198,872...157,328,325

G

NFKB inhibitor alpha

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in decreased expression of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

phosphoenolpyruvate carboxykinase 1

increases expression

Sodium Acetate results in increased expression of PCK1 mRNA

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of and results in increased phosphorylation of RELA protein]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of RELA mRNA]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

superoxide dismutase 2

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in decreased expression of SOD2 protein]

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

transforming growth factor, beta 1

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TGFB1 mRNA]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

toll-like receptor 2

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR2 mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR2 protein]

NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630

G

toll-like receptor 4

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR4 mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR4 protein]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TNF mRNA]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

UDP glucuronosyltransferase family 1 member A1

multiple interactions

Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of UGT1A1 mRNA]

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

xanthine dehydrogenase

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased activity of XDH protein]

NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268

sodium thiosulfate pentahydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

multiple interactions

sodium thiosulfate inhibits the reaction [Isoproterenol results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

sodium thiosulfate inhibits the reaction [Isoproterenol results in increased activity of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

myeloperoxidase

multiple interactions

sodium thiosulfate inhibits the reaction [Isoproterenol results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

tacrolimus hydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

increases expression

Tacrolimus results in increased expression of A2M mRNA

NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786

G

ATP binding cassette subfamily A member 1

multiple interactions
increases expression

[Sirolimus co-treated with Tacrolimus] results in increased expression of ABCA1 protein
Tacrolimus results in increased expression of ABCA1 mRNA

PMID:17016853 PMID:21865292

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

decreases activity

Tacrolimus results in decreased activity of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

affects export
decreases activity
multiple interactions
increases response to substance
increases export
affects response to substance

ABCB1 protein affects the export of Tacrolimus
Tacrolimus results in decreased activity of ABCB1 protein
[Tacrolimus binds to ABCB1 protein] inhibits the reaction [azidoprazosin binds to ABCB1 protein]; [Tacrolimus results in decreased activity of ABCB1 protein] which results in decreased export of Dexamethasone; Verapamil affects the reaction [ABCB1 protein results in increased export of Tacrolimus]
ABCB1 gene SNP results in increased susceptibility to Tacrolimus
ABCB1 protein affects the susceptibility to Tacrolimus

PMID:1381629 PMID:11920757 PMID:12352921 PMID:15919446 PMID:15964336 More...

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

acetyl-Coenzyme A acyltransferase 1B

decreases expression

Tacrolimus results in decreased expression of ACAA1B mRNA

NCBI chr 8:118,872,996...118,881,852
Ensembl chr 8:118,872,997...118,881,825

G

acyl-CoA dehydrogenase, long chain

decreases expression

Tacrolimus results in decreased expression of ACADL mRNA

NCBI chr 9:68,333,981...68,372,149
Ensembl chr 9:68,333,980...68,372,220

G

angiotensin converting enzyme 2

decreases expression

Tacrolimus results in decreased expression of ACE2 mRNA

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

acid phosphatase 5, tartrate resistant

multiple interactions

Tacrolimus inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein]

NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929

G

actin alpha 2, smooth muscle

increases expression

Tacrolimus results in increased expression of ACTA2 protein

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

activin A receptor type 1B

multiple interactions

[Tacrolimus inhibits the reaction [FKBP1A protein binds to ACVR1B protein]] which results in decreased ubiquitination of ACVR1B protein; Tacrolimus inhibits the reaction [FKBP1A protein binds to and results in decreased activity of ACVR1B protein]; Tacrolimus inhibits the reaction [FKBP1A protein promotes the reaction [SMURF1 protein binds to SMAD7 protein binds to ACVR1B protein]]

NCBI chr 7:132,286,266...132,329,679
Ensembl chr 7:132,286,275...132,329,673

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

increases expression

Tacrolimus results in increased expression of ADAMTS1 mRNA

NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103

G

ADAM metallopeptidase with thrombospondin type 1 motif, 2

increases expression

Tacrolimus results in increased expression of ADAMTS2 mRNA

NCBI chr10:34,920,992...35,126,465
Ensembl chr10:34,921,049...35,123,821

G

adenylate cyclase 9

multiple interactions

Tacrolimus inhibits the reaction [Calcium inhibits the reaction [Miconazole results in increased activity of ADCY9 protein]]

NCBI chr10:11,138,966...11,262,067
Ensembl chr10:11,139,446...11,262,066

G

adrenoceptor alpha 1D

increases expression

Tacrolimus results in increased expression of ADRA1D mRNA

NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354

G

allograft inflammatory factor 1

increases expression

Tacrolimus results in increased expression of AIF1 mRNA

NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668

G

aldehyde dehydrogenase 1 family, member A1

decreases expression

Tacrolimus results in decreased expression of ALDH1A1 mRNA

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

aldehyde dehydrogenase 2 family member

decreases expression

Tacrolimus results in decreased expression of ALDH2 mRNA

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

aldehyde dehydrogenase 9 family, member A1

decreases expression

Tacrolimus results in decreased expression of ALDH9A1 mRNA

NCBI chr13:79,505,738...79,522,539
Ensembl chr13:79,505,695...79,540,568

G

ALG3, alpha-1,3- mannosyltransferase

decreases expression

Tacrolimus results in decreased expression of ALG3 mRNA

NCBI chr11:80,300,487...80,306,014
Ensembl chr11:80,300,498...80,307,912

G

angiopoietin-like 6

increases expression

Tacrolimus results in increased expression of ANGPTL6 mRNA

NCBI chr 8:19,413,617...19,419,925
Ensembl chr 8:19,413,619...19,419,925

G

ankyrin repeat domain 1

increases expression

Tacrolimus results in increased expression of ANKRD1 mRNA

NCBI chr 1:233,815,851...233,834,891
Ensembl chr 1:233,815,851...233,834,919

G

ankyrin repeat domain 34A

decreases expression

Tacrolimus results in decreased expression of ANKRD34A mRNA

NCBI chr 2:184,129,830...184,135,075
Ensembl chr 2:184,129,238...184,135,116

G

alanyl aminopeptidase, membrane

increases secretion

Tacrolimus results in increased secretion of ANPEP protein

NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789

G

annexin A1

increases expression

Tacrolimus results in increased expression of ANXA1

NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343

G

amine oxidase, copper containing 1

increases expression

Tacrolimus results in increased expression of AOC1 mRNA

NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840

G

amphiregulin

increases expression

Tacrolimus results in increased expression of AREG mRNA

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

ADP-ribosylation factor related protein 1

increases expression

Tacrolimus results in increased expression of ARFRP1 mRNA

NCBI chr 3:168,466,351...168,473,960
Ensembl chr 3:168,466,496...168,473,914

G

Rho GTPase activating protein 45

increases expression

Tacrolimus results in increased expression of ARHGAP45 mRNA

NCBI chr 7:9,674,873...9,690,286
Ensembl chr 7:9,674,897...9,690,268

G

Rho guanine nucleotide exchange factor 11

increases expression

Tacrolimus results in increased expression of ARHGEF11 mRNA

NCBI chr 2:173,074,383...173,195,962
Ensembl chr 2:173,074,368...173,196,010

G

actin related protein 2/3 complex, subunit 5

increases expression

Tacrolimus results in increased expression of ARPC5 mRNA

NCBI chr13:64,904,504...64,913,413
Ensembl chr13:64,887,136...64,913,410

G

ARV1 homolog, fatty acid homeostasis modulator

increases expression

Tacrolimus results in increased expression of ARV1 mRNA

NCBI chr19:52,692,337...52,704,156
Ensembl chr19:52,692,337...52,704,156

G

ASXL transcriptional regulator 3

decreases expression

Tacrolimus results in decreased expression of ASXL3 mRNA

NCBI chr18:13,593,529...13,766,324
Ensembl chr18:13,593,985...13,762,427

G

activating transcription factor 3

increases expression

Tacrolimus results in increased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 4

increases expression

Tacrolimus results in increased expression of ATF4 mRNA

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

activating transcription factor 6

increases expression

Tacrolimus results in increased expression of ATF6 mRNA

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

ATPase Na+/K+ transporting subunit beta 1

decreases expression

Tacrolimus results in decreased expression of ATP1B1 mRNA

NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459

G

ATPase Na+/K+ transporting subunit beta 3

decreases expression

Tacrolimus results in decreased expression of ATP1B3 mRNA

NCBI chr 8:96,910,265...96,941,592
Ensembl chr 8:96,910,309...96,941,598

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

increases expression

Tacrolimus results in increased expression of ATP2A2 mRNA

NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101

G

beta-2 microglobulin

increases expression

Tacrolimus results in increased expression of B2M mRNA

NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766

G

BCL2-associated agonist of cell death

multiple interactions

Tacrolimus inhibits the reaction [Ammonium Chloride results in decreased phosphorylation of BAD protein]
Tacrolimus inhibits the reaction [Rotenone results in decreased phosphorylation of BAD protein]

PMID:15036616 PMID:15280438

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

basic leucine zipper ATF-like transcription factor 3

increases expression

Tacrolimus results in increased expression of BATF3 mRNA

NCBI chr13:102,689,657...102,701,241
Ensembl chr13:102,689,657...102,701,139

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of BAX protein]
Tacrolimus results in increased expression of BAX protein
[Tacrolimus co-treated with 3-nitropropionic acid] affects the localization of BAX protein

PMID:10205001 PMID:15571979 PMID:27606422 PMID:35033536

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions
decreases expression
increases expression

Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of BCL2 protein]
Tacrolimus results in decreased expression of BCL2 protein
[Tacrolimus co-treated with 3-nitropropionic acid] affects the localization of BCL2 protein
Tacrolimus results in increased expression of BCL2 protein

PMID:10205001 PMID:15571979 PMID:27606422

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions

Tacrolimus inhibits the reaction [Superantigens results in increased expression of BCL2L1 protein]

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

BCL3, transcription coactivator

increases expression

Tacrolimus results in increased expression of BCL3 mRNA

NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607

G

brain-derived neurotrophic factor

multiple interactions

Tacrolimus inhibits the reaction [decamethrin results in increased expression of BDNF exon]; Tacrolimus promotes the reaction [U 0126 inhibits the reaction [decamethrin results in increased expression of BDNF exon]]; U 0126 promotes the reaction [Tacrolimus inhibits the reaction [decamethrin results in increased expression of BDNF exon]]

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

baculoviral IAP repeat-containing 3

increases expression

Tacrolimus results in increased expression of BIRC3 mRNA

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

baculoviral IAP repeat-containing 5

decreases expression

Tacrolimus results in decreased expression of BIRC5 mRNA

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

bone morphogenetic protein 7

multiple interactions
decreases expression

Ramipril inhibits the reaction [Tacrolimus results in decreased expression of BMP7 protein]; valsartan inhibits the reaction [Tacrolimus results in decreased expression of BMP7 protein]

NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788

G

BTG anti-proliferation factor 2

increases expression

Tacrolimus results in increased expression of BTG2 mRNA

NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628

G

butyrophilin-like 9

decreases expression

Tacrolimus results in decreased expression of BTNL9 mRNA

NCBI chr10:33,466,059...33,489,229
Ensembl chr10:33,470,536...33,489,025

G

complement C1q A chain

increases expression

Tacrolimus results in increased expression of C1QA mRNA

NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534

G

complement C1q B chain

increases expression

Tacrolimus results in increased expression of C1QB mRNA

NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407

G

complement C1q C chain

increases expression

Tacrolimus results in increased expression of C1QC mRNA

NCBI chr 5:149,127,412...149,130,757
Ensembl chr 5:149,127,415...149,131,017

G

complement C2

increases expression

Tacrolimus results in increased expression of C2 mRNA

NCBI chr20:3,951,474...3,970,376
Ensembl chr20:3,951,474...3,976,505

G

complement C3

increases expression

Tacrolimus results in increased expression of C3 mRNA

PMID:21865292 PMID:29362864

NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429

G

complement C4B

increases expression

Tacrolimus results in increased expression of C4B mRNA

NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681

G

calbindin 1

decreases expression

Tacrolimus results in decreased expression of CALB1 mRNA; Tacrolimus results in decreased expression of CALB1 protein

PMID:14978156 PMID:21865292

NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431

G

calcitonin receptor

multiple interactions

Tacrolimus inhibits the reaction [TNFSF11 protein results in increased expression of CALCR mRNA]

NCBI chr 4:31,661,270...31,736,392
Ensembl chr 4:31,661,273...31,736,392

G

calreticulin

increases expression

Tacrolimus results in increased expression of CALR mRNA

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

calcium/calmodulin-dependent protein kinase ID

increases expression

Tacrolimus results in increased expression of CAMK1D mRNA

NCBI chr17:72,581,899...72,982,704
Ensembl chr17:72,581,979...72,980,556

G

capping actin protein, gelsolin like

increases expression

Tacrolimus results in increased expression of CAPG mRNA

NCBI chr 4:104,594,743...104,611,856
Ensembl chr 4:104,594,753...104,611,856

G

caspase 3

multiple interactions
increases cleavage
increases activity

Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [Thapsigargin results in increased activity of CASP3 protein]
Tacrolimus results in increased cleavage of CASP3 protein
Tacrolimus results in increased activity of CASP3 protein
MK0626 inhibits the reaction [Tacrolimus results in increased activity of CASP3 protein]; NGF protein inhibits the reaction [Tacrolimus results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [3-nitropropionic acid results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [[Lithium co-treated with Pilocarpine] results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [Oxygen deficiency results in increased activity of CASP3 protein]
Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [S-Nitrosoglutathione results in increased activity of CASP3 protein]

PMID:10205001 PMID:12642403 PMID:12871656 PMID:12892836 PMID:15207740 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions
increases expression

Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP8 protein]
Tacrolimus results in increased expression of CASP8 protein

PMID:15548389 PMID:27606422

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases expression

Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP9 protein]
Tacrolimus results in increased expression of CASP9 protein

PMID:15548389 PMID:27606422

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

increases expression
decreases response to substance

Tacrolimus results in increased expression of CAT protein
CAT protein results in decreased susceptibility to Tacrolimus

PMID:14675044 PMID:18766458

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

Cbl proto-oncogene like 1

increases expression

Tacrolimus results in increased expression of CBLL1 mRNA

NCBI chr 6:48,071,190...48,086,174
Ensembl chr 6:48,071,190...48,086,444

G

coiled-coil domain containing 88B

increases expression

Tacrolimus results in increased expression of CCDC88B mRNA

NCBI chr 1:204,036,913...204,052,878
Ensembl chr 1:204,036,918...204,052,970

G

C-C motif chemokine ligand 11

decreases expression

Tacrolimus results in decreased expression of CCL11 mRNA

NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926

G

C-C motif chemokine ligand 17

increases expression

Tacrolimus results in increased expression of CCL17 mRNA

NCBI chr19:10,202,128...10,203,903
Ensembl chr19:10,202,128...10,203,819

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

pyrrolidine dithiocarbamic acid inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]
Tacrolimus inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL2 protein]
7-oxozeanol inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; 7-oxozeanol inhibits the reaction [Tacrolimus results in increased expression of CCL2 protein]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Tacrolimus results in increased expression of CCL2 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; parthenolide inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL2 protein]; salubrinal inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; sulforaphane inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]

PMID:12472797 PMID:23958496 PMID:29362864 PMID:36416909

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 20

increases expression

Tacrolimus results in increased expression of CCL20 mRNA

NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629

G

C-C motif chemokine ligand 3

multiple interactions

Tacrolimus inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL3 protein]

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 5

decreases expression
increases expression
multiple interactions

Tacrolimus results in decreased expression of CCL5 mRNA
Tacrolimus results in increased expression of CCL5 mRNA
7-oxozeanol inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; parthenolide inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; salubrinal inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; sulforaphane inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]

PMID:15948978 PMID:23958496 PMID:25270620

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

C-C motif chemokine ligand 7

increases expression

Tacrolimus results in increased expression of CCL7 mRNA

PMID:23958496 PMID:29362864

NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303

G

C-C motif chemokine ligand 9

increases expression

Tacrolimus results in increased expression of CCL6 mRNA

PMID:21865292 PMID:29362864

NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369

G

cellular communication network factor 2

multiple interactions

Tacrolimus inhibits the reaction [Paraquat results in increased expression of CCN2 mRNA]; Tacrolimus inhibits the reaction [Paraquat results in increased secretion of CCN2 protein]

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cyclin A2

increases expression

Tacrolimus results in increased expression of CCNA2 mRNA

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin B2

decreases expression
increases expression

Tacrolimus results in decreased expression of CCNB2 mRNA
Tacrolimus results in increased expression of CCNB2 mRNA

PMID:16574167 PMID:29362864

NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874

G

C-C motif chemokine receptor 2

increases expression

Tacrolimus results in increased expression of CCR2 mRNA

NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100

G

C-C motif chemokine receptor 3

decreases expression

Tacrolimus results in decreased expression of CCR3 mRNA

NCBI chr 8:123,586,100...123,634,178
Ensembl chr 8:123,616,236...123,634,990

G

C-C motif chemokine receptor like 2

increases expression

Tacrolimus results in increased expression of CCRL2 mRNA

NCBI chr 8:111,034,279...111,036,914
Ensembl chr 8:111,034,279...111,036,664

G

Cd2 molecule

multiple interactions

Tacrolimus inhibits the reaction [CD2 protein results in increased expression of IL2 protein]

NCBI chr 2:188,710,895...188,724,044
Ensembl chr 2:188,710,900...188,724,026

G

CD44 molecule

increases expression

Tacrolimus results in increased expression of CD44 mRNA

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

Cd68 molecule

increases expression

Tacrolimus results in increased expression of CD68 mRNA

NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697

G

CD74 molecule

increases expression

Tacrolimus results in increased expression of CD74 mRNA

NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003

G

Cd80 molecule

decreases expression

Tacrolimus results in decreased expression of CD80 protein

NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030

G

CD83 molecule

increases expression

Tacrolimus results in increased expression of CD83 mRNA

NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083

G

CD86 molecule

decreases expression

Tacrolimus results in decreased expression of CD86 protein

NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818

G

cell division cycle associated 3

increases expression

Tacrolimus results in increased expression of CDCA3 mRNA

NCBI chr 4:157,634,775...157,638,799
Ensembl chr 4:157,634,928...157,638,799

G

cell division cycle associated 5

increases expression

Tacrolimus results in increased expression of CDCA5 mRNA

NCBI chr 1:203,378,550...203,392,027
Ensembl chr 1:203,378,577...203,392,023

G

cell division cycle associated 8

increases expression

Tacrolimus results in increased expression of CDCA8 mRNA

NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629

G

cadherin 1

decreases expression

Tacrolimus results in decreased expression of CDH1 protein

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 11

increases expression

Tacrolimus results in increased expression of CDH11 mRNA

NCBI chr19:2,148,447...2,305,754
Ensembl chr19:2,148,458...2,304,272

G

cadherin 16

decreases expression

Tacrolimus results in decreased expression of CDH16 mRNA

NCBI chr19:360,824...371,008
Ensembl chr19:360,824...371,007

G

cyclin-dependent kinase inhibitor 1B

increases expression

Tacrolimus results in increased expression of CDKN1B mRNA

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

CCAAT/enhancer binding protein alpha

increases expression

Tacrolimus results in increased expression of CEBPA mRNA

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

centromere protein W

increases expression

Tacrolimus results in increased expression of CENPW mRNA

NCBI chr 1:27,525,324...27,530,464
Ensembl chr 1:27,525,324...27,530,464

G

complement factor I

increases expression

Tacrolimus results in increased expression of CFI mRNA

NCBI chr 2:218,389,079...218,430,565
Ensembl chr 2:218,387,990...218,430,561

G

cytoskeleton associated protein 2

increases expression

Tacrolimus results in increased expression of CKAP2 mRNA

NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913

G

cytoskeleton-associated protein 4

increases expression

Tacrolimus results in increased expression of CKAP4 mRNA

NCBI chr 7:19,230,814...19,238,914
Ensembl chr 7:19,230,203...19,238,914

G

claudin 1

decreases expression

Tacrolimus results in decreased expression of CLDN1 mRNA

NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724

G

claudin 4

increases expression

Tacrolimus results in increased expression of CLDN4 mRNA

NCBI chr12:21,751,638...21,753,436
Ensembl chr12:21,751,331...21,753,436

G

claudin 7

increases expression

Tacrolimus results in increased expression of CLDN7 mRNA

NCBI chr10:54,689,684...54,692,177
Ensembl chr10:54,689,987...54,692,171

G

C-type lectin domain containing 7A

increases expression

Tacrolimus results in increased expression of CLEC7A mRNA

NCBI chr 4:162,902,731...162,913,931
Ensembl chr 4:162,902,732...162,913,897

G

CDC-like kinase 3

increases expression

Tacrolimus results in increased expression of CLK3 mRNA

NCBI chr 8:58,152,155...58,167,196
Ensembl chr 8:58,152,155...58,168,181

G

clusterin

increases expression

Tacrolimus results in increased expression of CLU mRNA

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

cochlin

increases expression

Tacrolimus results in increased expression of COCH mRNA

NCBI chr 6:69,031,139...69,045,124
Ensembl chr 6:69,031,167...69,045,109

G

collagen type I alpha 1 chain

increases expression

Tacrolimus results in increased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

increases expression

Tacrolimus results in increased expression of COL1A2 mRNA

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

collagen type III alpha 1 chain

increases expression

Tacrolimus results in increased expression of COL3A1 mRNA

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

COP9 signalosome subunit 8

increases expression

Tacrolimus results in increased expression of COPS8 mRNA

NCBI chr 9:91,207,427...91,217,258
Ensembl chr 9:91,207,395...91,217,258

G

ceruloplasmin

increases expression

Tacrolimus results in increased expression of CP mRNA

NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075

G

cAMP responsive element binding protein 3-like 3

decreases expression

Tacrolimus results in decreased expression of CREB3L3 mRNA

NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048

G

cysteine-rich with EGF-like domains 2

increases expression

Tacrolimus results in increased expression of CRELD2 mRNA

NCBI chr 7:119,909,626...119,916,556
Ensembl chr 7:119,909,633...119,916,543

G

colony stimulating factor 1

increases expression

Tacrolimus results in increased expression of CSF1 mRNA

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

colony stimulating factor 2

decreases expression
increases expression
multiple interactions

Tacrolimus results in decreased expression of CSF2 protein
Tacrolimus results in increased expression of CSF2 mRNA
Sirolimus inhibits the reaction [Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of CSF2 protein]]; Tacrolimus inhibits the reaction [[Calcimycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CSF2 protein]

PMID:1376361 PMID:11407316 PMID:23958496

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

colony stimulating factor 2 receptor subunit beta

increases expression

Tacrolimus results in increased expression of CSF2RB2 mRNA

NCBI chr 7:109,876,919...109,901,589
Ensembl chr 7:109,886,425...109,904,157

G

cathepsin L

multiple interactions
increases expression

Tacrolimus inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CTSL protein]
Tacrolimus results in increased expression of CTSL mRNA

PMID:18172886 PMID:21865292 PMID:25270620

NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548

G

C-X-C motif chemokine ligand 10

increases expression

Tacrolimus results in increased expression of CXCL10 mRNA

PMID:21865292 PMID:23958496 PMID:25270620

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 11

increases expression

Tacrolimus results in increased expression of CXCL11 mRNA

NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271

G

cytochrome b-245 alpha chain

multiple interactions
increases expression

Ramipril inhibits the reaction [Tacrolimus results in increased expression of CYBA mRNA]

NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721

G

cytochrome P450, family 27, subfamily b, polypeptide 1

increases expression

Tacrolimus results in increased expression of CYP27B1 mRNA

NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:62,871,297...62,876,241

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions

CYP2C19 affects the reaction [Lansoprazole affects the susceptibility to Tacrolimus]; CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole]; CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Rabeprazole]; CYP2C19 gene mutant form affects the susceptibility to [Lansoprazole co-treated with Tacrolimus]

PMID:15010519 PMID:15285851 PMID:17377957

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases metabolic processing
affects metabolic processing
decreases methylation
multiple interactions

CYP3A4 protein results in increased metabolism of Tacrolimus
CYP3A4 protein affects the metabolism of Tacrolimus
CYP3A4 protein results in decreased methylation of Tacrolimus
Metronidazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Tacrolimus]

PMID:15010519 PMID:15855244 PMID:15919446 PMID:15951320 PMID:15964336

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions
decreases methylation
affects metabolic processing
affects response to substance

CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole]; CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Rabeprazole]; CYP3A5 gene polymorphism affects the reaction [Ketoconazole results in decreased metabolism of Tacrolimus]
CYP3A5 protein results in decreased methylation of Tacrolimus
CYP3A5 gene polymorphism affects the metabolism of Tacrolimus; CYP3A5 gene SNP affects the metabolism of Tacrolimus; CYP3A5 protein affects the metabolism of Tacrolimus; CYP3A5 protein polymorphism affects the metabolism of Tacrolimus
CYP3A5 gene affects the susceptibility to Tacrolimus; CYP3A5 polymorphism affects the susceptibility to Tacrolimus

PMID:15502717 PMID:15723604 PMID:15729180 PMID:15808586 PMID:15919447 More...

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

decorin

increases expression

Tacrolimus results in increased expression of DCN mRNA

NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

salubrinal promotes the reaction [Tacrolimus results in increased expression of DDIT3 protein]
Tacrolimus results in increased expression of DDIT3 mRNA

PMID:23958496 PMID:25270620

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

DNA-damage-inducible transcript 4-like

decreases expression

Tacrolimus results in decreased expression of DDIT4L mRNA

NCBI chr 2:226,128,273...226,131,044
Ensembl chr 2:226,128,276...226,131,375

G

24-dehydrocholesterol reductase

decreases expression

Tacrolimus results in decreased expression of DHCR24 mRNA

NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137

G

DnaJ heat shock protein family (Hsp40) member C30

decreases expression

Tacrolimus results in decreased expression of DNAJC30 mRNA

NCBI chr12:21,628,319...21,629,398
Ensembl chr12:21,626,450...21,629,408

G

dynamin 1-like

multiple interactions

PINK1 protein affects the reaction [Tacrolimus results in increased phosphorylation of DNM1L protein]
Tacrolimus inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]

PMID:19492085 PMID:26318285

NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482

G

double C2 domain alpha

decreases expression

Tacrolimus results in decreased expression of DOC2A mRNA

NCBI chr 1:181,457,415...181,462,528
Ensembl chr 1:181,458,390...181,462,030

G

dedicator of cytokinesis 10

increases expression

Tacrolimus results in increased expression of DOCK10 mRNA

NCBI chr 9:81,843,599...82,101,540
Ensembl chr 9:81,843,604...82,101,525

G

dipeptidylpeptidase 4

increases activity
multiple interactions

Tacrolimus results in increased activity of DPP4 protein
MK0626 inhibits the reaction [Tacrolimus results in increased activity of DPP4 protein]

NCBI chr 3:46,962,233...47,043,870
Ensembl chr 3:46,962,243...47,043,901

G

dopamine receptor D2

affects activity
multiple interactions

Tacrolimus affects the activity of DRD2 protein
Sulpiride inhibits the reaction [Tacrolimus affects the activity of DRD2 protein]

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

enoyl-CoA hydratase 1

decreases expression

Tacrolimus results in decreased expression of ECH1 mRNA

NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795

G

ER degradation enhancing alpha-mannosidase like protein 1

increases expression

Tacrolimus results in increased expression of EDEM1 mRNA

NCBI chr 4:141,797,631...141,829,717
Ensembl chr 4:141,797,701...141,829,717

G

endothelin 1

increases expression

Tacrolimus results in increased expression of EDN1 mRNA; Tacrolimus results in increased expression of EDN1 protein

PMID:9517403 PMID:9931093

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

endothelin receptor type A

increases activity
increases expression

Tacrolimus results in increased activity of EDNRA protein
Tacrolimus results in increased expression of EDNRA mRNA

PMID:8587392 PMID:15964565

NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049

G

EGF containing fibulin extracellular matrix protein 2

increases expression

Tacrolimus results in increased expression of EFEMP2 mRNA

NCBI chr 1:202,781,692...202,789,784
Ensembl chr 1:202,781,665...202,789,414

G

early growth response 1

increases expression

Tacrolimus results in increased expression of EGR1 mRNA

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

early growth response 2

increases expression

Tacrolimus results in increased expression of EGR2 mRNA

NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562

G

eukaryotic translation initiation factor 4E binding protein 1

multiple interactions

Tacrolimus inhibits the reaction [Sirolimus results in decreased phosphorylation of and results in increased activity of EIF4EBP1 protein]

NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984

G

elaC ribonuclease Z 2

decreases expression

Tacrolimus results in decreased expression of ELAC2 mRNA

NCBI chr10:49,632,308...49,655,614
Ensembl chr10:49,632,378...49,655,614

G

endoplasmic reticulum to nucleus signaling 1

increases phosphorylation

Tacrolimus results in increased phosphorylation of ERN1 protein

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

endoplasmic reticulum oxidoreductase 1 alpha

increases expression

Tacrolimus results in increased expression of ERO1A mRNA

NCBI chr15:18,495,037...18,530,440
Ensembl chr15:18,492,945...18,530,478

G

exosome component 4

decreases expression

Tacrolimus results in decreased expression of EXOSC4 mRNA

NCBI chr 7:108,047,831...108,050,573
Ensembl chr 7:108,047,831...108,050,573

G

coagulation factor II (thrombin) receptor

decreases expression

Tacrolimus results in decreased expression of F2R mRNA

NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870

G

fatty acid binding protein 2

decreases expression

Tacrolimus results in decreased expression of FABP2 mRNA

NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089

G

Fas cell surface death receptor

multiple interactions

Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP8 protein]; Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP9 protein]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

decreases secretion

Tacrolimus results in decreased secretion of FASLG protein

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

fibulin 1

increases expression

Tacrolimus results in increased expression of FBLN1 mRNA

NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075

G

fibrinogen alpha chain

increases expression

Tacrolimus results in increased expression of FGA mRNA

NCBI chr 2:168,374,120...168,381,523
Ensembl chr 2:168,374,120...168,381,528

G

fibrinogen beta chain

increases expression

Tacrolimus results in increased expression of FGB mRNA

NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979

G

FYVE, RhoGEF and PH domain containing 2

increases expression

Tacrolimus results in increased expression of FGD2 mRNA

NCBI chr20:7,424,795...7,441,603
Ensembl chr20:7,424,790...7,441,603

G

fibroblast growth factor 21

decreases expression

Tacrolimus results in decreased expression of FGF21 mRNA

NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454

G

fibrinogen-like 2

increases expression

Tacrolimus results in increased expression of FGL2 mRNA

PMID:21865292 PMID:29362864

NCBI chr 4:13,710,566...13,716,207
Ensembl chr 4:13,710,575...13,716,207

G

four and a half LIM domains 2

increases expression

Tacrolimus results in increased expression of FHL2 mRNA

NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192

G

FKBP prolyl isomerase 1A

multiple interactions
increases expression

[Tacrolimus binds to FKBP1A protein] inhibits the reaction [Sirolimus binds to FKBP1A protein]; [Tacrolimus inhibits the reaction [FKBP1A protein binds to ACVR1B protein]] which results in decreased ubiquitination of ACVR1B protein; Tacrolimus inhibits the reaction [FKBP1A protein binds to and results in decreased activity of ACVR1B protein]; Tacrolimus inhibits the reaction [FKBP1A protein promotes the reaction [SMURF1 protein binds to SMAD7 protein binds to ACVR1B protein]]
Tacrolimus results in increased expression of FKBP1A protein

PMID:10361256 PMID:11041285 PMID:16720724

NCBI chr 3:140,040,359...140,060,107
Ensembl chr 3:140,040,278...140,060,743

G

FKBP prolyl isomerase 5

multiple interactions

Tacrolimus inhibits the reaction [NR3C1 protein binds to FKBP5 protein]

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

Fms related receptor tyrosine kinase 3

increases expression

Tacrolimus results in increased expression of FLT3 mRNA

NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474

G

flavin containing dimethylaniline monoxygenase 2

increases expression

Tacrolimus results in increased expression of FMO2 mRNA

NCBI chr13:75,221,149...75,244,377
Ensembl chr13:75,224,402...75,244,308

G

fibronectin 1

multiple interactions
increases expression

Tacrolimus inhibits the reaction [NPR1 protein affects the expression of FN1 mRNA]
Tacrolimus results in increased expression of FN1 mRNA

PMID:15939815 PMID:29362864

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

fibronectin type III domain containing 3a

increases expression

Tacrolimus results in increased expression of FNDC3A mRNA

NCBI chr15:47,689,909...47,867,354
Ensembl chr15:47,689,919...47,866,784

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

Tacrolimus results in increased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FOS like 1, AP-1 transcription factor subunit

increases expression

Tacrolimus results in increased expression of FOSL1 mRNA

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

guanylate binding protein 1

decreases expression

Tacrolimus results in decreased expression of GBP1 mRNA

NCBI chr 2:231,398,136...231,432,773
Ensembl chr 2:231,398,163...231,432,131
Ensembl chr 2:231,398,163...231,432,131

G

GC, vitamin D binding protein

decreases expression
increases expression

Tacrolimus results in decreased expression of GC mRNA
Tacrolimus results in increased expression of GC mRNA

PMID:21865292 PMID:29362864

NCBI chr14:18,632,146...18,667,563
Ensembl chr14:18,632,135...18,667,567

G

glucagon

multiple interactions
decreases secretion

MK0626 inhibits the reaction [Tacrolimus results in decreased secretion of GCG protein modified form]

NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929

G

GINS complex subunit 2

increases expression

Tacrolimus results in increased expression of GINS2 mRNA

NCBI chr19:48,626,770...48,639,523
Ensembl chr19:48,626,770...48,639,339

G

gap junction protein, beta 1

increases expression

Tacrolimus results in increased expression of GJB1 mRNA

NCBI chr X:66,501,848...66,509,783
Ensembl chr X:66,501,820...66,509,925

G

glycine decarboxylase

decreases expression

Tacrolimus results in decreased expression of GLDC mRNA

NCBI chr 1:227,883,249...227,962,119
Ensembl chr 1:227,883,249...227,962,097

G

glucagon-like peptide 1 receptor

decreases expression
multiple interactions

Tacrolimus results in decreased expression of GLP1R protein
MK0626 inhibits the reaction [Tacrolimus results in decreased expression of GLP1R protein]

NCBI chr20:8,972,004...9,010,241
Ensembl chr20:8,972,004...9,010,241

G

glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1

decreases expression

Tacrolimus results in decreased expression of GPIHBP1 mRNA

NCBI chr 7:107,285,584...107,288,702
Ensembl chr 7:107,285,654...107,288,702

G

GPN-loop GTPase 2

increases expression

Tacrolimus results in increased expression of GPN2 mRNA

NCBI chr 5:145,809,455...145,817,252
Ensembl chr 5:145,809,651...145,817,252

G

glycoprotein nmb

increases expression

Tacrolimus results in increased expression of GPNMB mRNA

NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367

G

granulin precursor

increases expression

Tacrolimus results in increased expression of GRN mRNA

NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775

G

glycogen synthase kinase 3 alpha

multiple interactions
increases phosphorylation

[GSK3A protein co-treated with GSK3B protein] affects the reaction [Tacrolimus results in increased expression of SNAI1 protein]
Tacrolimus results in increased phosphorylation of GSK3A protein

NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802

G

glycogen synthase kinase 3 beta

multiple interactions
increases phosphorylation

[GSK3A protein co-treated with GSK3B protein] affects the reaction [Tacrolimus results in increased expression of SNAI1 protein]
Tacrolimus results in increased phosphorylation of GSK3B protein

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

GTP binding protein 4

decreases expression

Tacrolimus results in decreased expression of GTPBP4 mRNA

NCBI chr17:61,308,033...61,328,184
Ensembl chr17:61,308,014...61,418,009

G

guanylate cyclase activator 2A

increases expression

Tacrolimus results in increased expression of GUCA2A mRNA

NCBI chr 5:133,237,177...133,239,019
Ensembl chr 5:133,237,177...133,239,018

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta

decreases expression

Tacrolimus results in decreased expression of HADHB mRNA

NCBI chr 6:26,153,572...26,187,668
Ensembl chr 6:26,153,578...26,184,869

G

hepatitis A virus cellular receptor 1

increases expression

Tacrolimus results in increased expression of HAVCR1 mRNA

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

homocysteine inducible ER protein with ubiquitin like domain 1

increases expression

Tacrolimus results in increased expression of HERPUD1 mRNA

PMID:23958496 PMID:25270620

NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424

G

hexosaminidase subunit alpha

increases expression

Tacrolimus results in increased expression of HEXA mRNA

NCBI chr 8:59,936,526...59,961,654
Ensembl chr 8:59,936,660...59,962,013

G

hepatocyte growth factor-regulated tyrosine kinase substrate

increases expression

Tacrolimus results in increased expression of HGS mRNA

NCBI chr10:105,739,617...105,757,838
Ensembl chr10:105,739,296...105,757,835

G

hexokinase 2

increases expression

Tacrolimus results in increased expression of HK2 mRNA

NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530

G

hexokinase 3

increases expression

Tacrolimus results in increased expression of HK3 mRNA

NCBI chr17:9,596,950...9,614,847
Ensembl chr17:9,599,865...9,614,863

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

decreases expression

Tacrolimus results in decreased expression of HMGCS2 mRNA

NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130

G

heme oxygenase 1

increases expression
decreases expression
multiple interactions

Tacrolimus results in increased expression of HMOX1 mRNA; Tacrolimus results in increased expression of HMOX1 protein
Tacrolimus results in decreased expression of HMOX1 protein
MK0626 inhibits the reaction [Tacrolimus results in decreased expression of HMOX1 protein]

PMID:23958496 PMID:24959755 PMID:26260164 PMID:29362864

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

HNF1 homeobox B

decreases expression

Tacrolimus results in decreased expression of HNF1B mRNA

NCBI chr10:68,735,894...68,789,888
Ensembl chr10:68,735,894...68,789,888

G

hydroxysteroid dehydrogenase like 2

decreases expression

Tacrolimus results in decreased expression of HSDL2 mRNA

NCBI chr 5:74,443,933...74,479,104
Ensembl chr 5:74,443,872...74,479,839

G

heat shock protein family A (Hsp70) member 5

increases expression

Tacrolimus results in increased expression of HSPA5 mRNA

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 8

multiple interactions
increases expression

Tacrolimus inhibits the reaction [Acrylamide results in decreased expression of HSPA8 protein]
Tacrolimus results in increased expression of HSPA8 protein

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

5-hydroxytryptamine receptor 1A

decreases expression

Tacrolimus results in decreased expression of HTR1A protein

NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442

G

5-hydroxytryptamine receptor 1B

decreases expression

Tacrolimus results in decreased expression of HTR1B protein

NCBI chr 8:82,513,572...82,534,670
Ensembl chr 8:82,517,360...82,534,549

G

intercellular adhesion molecule 1

decreases expression
increases expression

Tacrolimus results in decreased expression of ICAM1; Tacrolimus results in decreased expression of ICAM1 protein
Tacrolimus results in increased expression of ICAM1 mRNA

PMID:9794552 PMID:10385251 PMID:23958496

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

inhibitor of DNA binding 1

increases expression

Tacrolimus results in increased expression of ID1 mRNA

PMID:25270620 PMID:29362864

NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419

G

inhibitor of DNA binding 2

increases expression

Tacrolimus results in increased expression of ID2 mRNA

NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400

G

inhibitor of DNA binding 3

increases expression

Tacrolimus results in increased expression of ID3 mRNA

NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349

G

inhibitor of DNA binding 4

increases expression

Tacrolimus results in increased expression of ID4 mRNA

NCBI chr17:16,389,387...16,391,956
Ensembl chr17:16,389,387...16,392,470

G

isopentenyl-diphosphate delta isomerase 1

decreases expression

Tacrolimus results in decreased expression of IDI1 mRNA

NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357

G

interferon, alpha-inducible protein 27 like 2A

increases expression

Tacrolimus results in increased expression of IFI27L2A mRNA

NCBI chr 6:122,598,872...122,600,358
Ensembl chr 6:122,598,872...122,600,360

G

interferon gamma

multiple interactions
decreases expression
decreases secretion

[Tacrolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IFNG protein]; Tacrolimus inhibits the reaction [enterotoxin A, Staphylococcal results in increased expression of IFNG protein]; Tacrolimus inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IFNG mRNA]
Tacrolimus results in decreased expression of IFNG protein
Tacrolimus results in decreased expression of IFNG mRNA; Tacrolimus results in decreased expression of IFNG protein
[Tacrolimus co-treated with TAK 779] results in decreased expression of IFNG protein
Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of BCL2 protein]; Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of BAX protein]; Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TRP53 protein]
Tacrolimus results in decreased secretion of IFNG protein

PMID:1371491 PMID:8986461 PMID:10205001 PMID:11407316 PMID:11692113 More...

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 1

increases response to substance

IGF1 protein results in increased susceptibility to Tacrolimus

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor binding protein 1

decreases expression
increases expression

Tacrolimus results in decreased expression of IGFBP1 mRNA
Tacrolimus results in increased expression of IGFBP1 mRNA

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

insulin-like growth factor binding protein 5

increases expression

Tacrolimus results in increased expression of IGFBP5 mRNA

NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156

G

interleukin 12B

multiple interactions

Tacrolimus inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL12B protein]

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 15 receptor subunit alpha

increases expression

Tacrolimus results in increased expression of IL15RA mRNA

NCBI chr17:66,802,300...66,831,973
Ensembl chr17:66,802,334...66,832,278

G

interleukin 17 receptor A

increases expression

Tacrolimus results in increased expression of IL17RA mRNA

NCBI chr 4:153,667,534...153,690,174
Ensembl chr 4:153,667,534...153,690,174

G

interleukin 1 beta

increases expression

Tacrolimus results in increased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor antagonist

increases expression

Tacrolimus results in increased expression of IL1RN mRNA

NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445

G

interleukin 2

multiple interactions
decreases expression

[Tacrolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL2 protein]; Tacrolimus inhibits the reaction [CD2 protein results in increased expression of IL2 protein]; Tacrolimus inhibits the reaction [enterotoxin A, Staphylococcal results in increased expression of IL2 protein]; Tacrolimus inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL2 mRNA]; Tacrolimus inhibits the reaction [Zinc Sulfate inhibits the reaction [Mitogens results in increased expression of IL2 mRNA]]
Tacrolimus results in decreased expression of IL2 mRNA; Tacrolimus results in decreased expression of IL2 protein
Tacrolimus affects the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] affects the expression of IL2 protein]; Tacrolimus inhibits the reaction [Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]]

PMID:1371491 PMID:1614535 PMID:1701765 PMID:1705513 PMID:8986461 More...

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 23 subunit alpha

increases expression

Tacrolimus results in increased expression of IL23A mRNA

NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923

G

interleukin 2 receptor subunit alpha

decreases expression

Tacrolimus results in decreased expression of IL2RA protein

NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697

G

interleukin 3

decreases expression
multiple interactions

Tacrolimus results in decreased expression of IL3 protein
Sirolimus inhibits the reaction [Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL3 protein]]; Tacrolimus inhibits the reaction [[Calcimycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL3 protein]

PMID:1376361 PMID:11407316

NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066

G

interleukin 4

multiple interactions
decreases expression

Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL4 protein]
Tacrolimus results in decreased expression of IL4 mRNA; Tacrolimus results in decreased expression of IL4 protein
Tacrolimus inhibits the reaction [bisphenol A promotes the reaction [NFATC3 protein binds to IL4 promoter]]; Tacrolimus inhibits the reaction [bisphenol A results in increased expression of IL4 protein]; Tacrolimus inhibits the reaction [nonylphenol promotes the reaction [NFATC3 protein binds to IL4 promoter]]; Tacrolimus inhibits the reaction [nonylphenol results in increased expression of IL4 protein]

PMID:1371491 PMID:10685002 PMID:11407316 PMID:12709020 PMID:16368244

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 5

multiple interactions
decreases expression

Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL5 protein]
Tacrolimus results in decreased expression of IL5 mRNA; Tacrolimus results in decreased expression of IL5 protein

PMID:1371491 PMID:7540862 PMID:11407316 PMID:15948978

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

interleukin 6

multiple interactions
increases expression
decreases expression

[Tacrolimus co-treated with quinapril] results in decreased expression of IL6 protein; [Tacrolimus co-treated with quinapril] results in increased expression of IL6 protein; [Tacrolimus co-treated with Valsartan] results in decreased expression of IL6 protein; [Tacrolimus co-treated with Valsartan] results in increased expression of IL6 protein
Tacrolimus results in increased expression of IL6 mRNA
parthenolide inhibits the reaction [Tacrolimus results in increased expression of IL6 mRNA]; sulforaphane inhibits the reaction [Tacrolimus results in increased expression of IL6 mRNA]
Tacrolimus results in increased expression of IL6 protein
Tacrolimus results in decreased expression of IL6 protein

PMID:16549154 PMID:23958496

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

IMP U3 small nucleolar ribonucleoprotein 4

decreases expression

Tacrolimus results in decreased expression of IMP4 mRNA

NCBI chr 9:36,654,127...36,659,265
Ensembl chr 9:36,654,401...36,660,075

G

INO80 complex subunit E

decreases expression

Tacrolimus results in decreased expression of INO80E mRNA

NCBI chr 1:181,461,406...181,472,059
Ensembl chr 1:181,461,408...181,472,469

G

insulin 1

decreases expression
multiple interactions

Tacrolimus results in decreased expression of INS1 protein
MK0626 inhibits the reaction [Tacrolimus results in decreased expression of INS1 protein]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

decreases expression

Tacrolimus results in decreased expression of INS protein

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

interleukin-1 receptor-associated kinase 1

increases phosphorylation

Tacrolimus results in increased phosphorylation of IRAK1 protein

NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521

G

integrin subunit alpha L

decreases expression

Tacrolimus results in decreased expression of ITGAL

NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732

G

Janus kinase 2

increases phosphorylation

Tacrolimus results in increased phosphorylation of JAK2 protein

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

G

Jun proto-oncogene, AP-1 transcription factor subunit

decreases expression

Tacrolimus results in decreased expression of JUN protein

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

increases expression

Tacrolimus results in increased expression of JUNB mRNA

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

kinesin-associated protein 3

decreases expression

Tacrolimus results in decreased expression of KIFAP3 mRNA

NCBI chr13:76,127,702...76,264,654
Ensembl chr13:76,127,696...76,264,650

G

kinesin family member C1

decreases expression

Tacrolimus results in decreased expression of KIFC1 mRNA

NCBI chr20:4,998,832...5,017,107
Ensembl chr20:4,999,047...5,017,105

G

KLF transcription factor 5

increases expression

Tacrolimus results in increased expression of KLF5 mRNA

NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445

G

KLF transcription factor 6

increases expression

Tacrolimus results in increased expression of KLF6 mRNA

NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570

G

kallikrein 1-related peptidase C10

increases expression

Tacrolimus results in increased expression of KLK1C10 mRNA

NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052

G

kallikrein 1-related peptidase C9

increases expression

Tacrolimus results in increased expression of KLK1C9 mRNA

NCBI chr 1:94,597,359...94,601,245
Ensembl chr 1:94,597,359...94,601,245

G

KRAS proto-oncogene, GTPase

increases expression

Tacrolimus results in increased expression of KRAS mRNA

NCBI chr 4:178,185,418...178,218,484

G

keratin 20

increases expression

Tacrolimus results in increased expression of KRT20 mRNA

NCBI chr10:84,384,790...84,394,125
Ensembl chr10:84,384,802...84,394,107

G

laminin subunit gamma 2

increases expression

Tacrolimus results in increased expression of LAMC2 mRNA

NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200

G

lipopolysaccharide binding protein

increases expression

Tacrolimus results in increased expression of LBP mRNA

NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586

G

lipocalin 2

increases expression

Tacrolimus results in increased expression of LCN2 mRNA

PMID:21865292 PMID:29362864

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

lipoic acid synthetase

decreases expression

Tacrolimus results in decreased expression of LIAS mRNA

NCBI chr14:42,876,699...42,893,824
Ensembl chr14:42,876,699...42,893,783

G

LIF, interleukin 6 family cytokine

increases expression

Tacrolimus results in increased expression of LIF mRNA

NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482

G

LIM domain kinase 1

increases expression

Tacrolimus results in increased expression of LIMK1 mRNA

NCBI chr12:22,026,697...22,060,605
Ensembl chr12:22,026,672...22,060,606

G

LLGL scribble cell polarity complex component 1

increases expression

Tacrolimus results in increased expression of LLGL1 mRNA

NCBI chr10:45,379,423...45,394,096
Ensembl chr10:45,379,515...45,394,094

G

lymphotoxin alpha

multiple interactions

Tacrolimus inhibits the reaction [enterotoxin A, Staphylococcal results in increased expression of LTA protein]

NCBI chr20:3,618,853...3,621,324
Ensembl chr20:3,618,853...3,620,859

G

lactotransferrin

increases expression

Tacrolimus results in increased expression of LTF mRNA

NCBI chr 8:110,999,948...111,022,795
Ensembl chr 8:110,999,948...111,022,795

G

lymphocyte antigen 86

increases expression

Tacrolimus results in increased expression of LY86 mRNA

NCBI chr17:27,415,807...27,499,695
Ensembl chr17:27,415,830...27,487,260

G

lymphatic vessel endothelial hyaluronan receptor 1

decreases expression

Tacrolimus results in decreased expression of LYVE1 mRNA

NCBI chr 1:164,962,872...164,976,309
Ensembl chr 1:164,962,872...164,976,309

G

MAF bZIP transcription factor F

increases expression

Tacrolimus results in increased expression of MAFF mRNA

NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851

G

MAF bZIP transcription factor K

increases expression

Tacrolimus results in increased expression of MAFK mRNA

NCBI chr12:14,834,628...14,856,414
Ensembl chr12:14,833,984...14,837,048
Ensembl chr12:14,833,984...14,837,048

G

mesencephalic astrocyte-derived neurotrophic factor

increases expression

Tacrolimus results in increased expression of MANF mRNA

NCBI chr 8:107,500,856...107,551,595
Ensembl chr 8:107,548,352...107,551,438

G

mitogen activated protein kinase kinase kinase 7

increases phosphorylation

Tacrolimus results in increased phosphorylation of MAP3K7 protein

NCBI chr 5:46,356,973...46,415,597
Ensembl chr 5:46,357,931...46,415,597

G

mitogen-activated protein kinase 8

decreases activity
multiple interactions

Tacrolimus results in decreased activity of MAPK8 protein
Tacrolimus inhibits the reaction [Oxygen deficiency results in increased activity of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

muscleblind-like splicing regulator 2

decreases expression

Tacrolimus results in decreased expression of MBNL2 mRNA

NCBI chr15:97,385,278...97,542,924
Ensembl chr15:97,385,244...97,542,937

G

melanoma cell adhesion molecule

decreases expression

Tacrolimus results in decreased expression of MCAM mRNA

NCBI chr 8:44,479,391...44,487,575
Ensembl chr 8:44,479,376...44,487,571

G

microspherule protein 1

decreases expression

Tacrolimus results in decreased expression of MCRS1 mRNA

NCBI chr 7:130,383,853...130,392,667
Ensembl chr 7:130,383,853...130,392,685

G

methyltransferase 1, tRNA methylguanosine

increases expression

Tacrolimus results in increased expression of METTL1 mRNA

NCBI chr 7:62,864,860...62,869,202
Ensembl chr 7:62,864,853...62,869,202

G

major facilitator superfamily domain containing 1

increases expression

Tacrolimus results in increased expression of MFSD1 mRNA

NCBI chr 2:151,846,130...151,866,168
Ensembl chr 2:151,846,146...151,867,045

G

monoglyceride lipase

decreases expression

Tacrolimus results in decreased expression of MGLL mRNA

NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179

G

microRNA 146a

increases expression

Tacrolimus results in increased expression of MIR146 mRNA

NCBI chr10:27,848,516...27,848,610
Ensembl chr10:27,848,516...27,848,610

G

microRNA 146b

increases expression

Tacrolimus results in increased expression of MIR146B mRNA

NCBI chr 1:245,203,438...245,203,525
Ensembl chr 1:245,203,438...245,203,525

G

microRNA 193a

decreases expression

Tacrolimus results in decreased expression of MIR193A mRNA

NCBI chr10:64,672,343...64,672,454
Ensembl chr10:64,672,343...64,672,454

G

microRNA 200b

decreases expression

Tacrolimus results in decreased expression of MIR200B mRNA

NCBI chr 5:166,649,272...166,649,366
Ensembl chr 5:166,649,272...166,649,366

G

microRNA 21

increases expression

Tacrolimus results in increased expression of MIR21A mRNA

NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348

G

microRNA 214

increases expression

Tacrolimus results in increased expression of MIR214 mRNA

NCBI chr13:74,588,374...74,588,481
Ensembl chr13:74,588,372...74,588,481

G

microRNA 34b

increases expression

Tacrolimus results in increased expression of MIR34B mRNA

NCBI chr 8:51,410,244...51,410,327
Ensembl chr 8:51,410,244...51,410,327

G

microRNA 551b

decreases expression

Tacrolimus results in decreased expression of MIR551B mRNA

NCBI chr 2:113,989,203...113,989,300
Ensembl chr 2:113,989,203...113,989,300

G

MOB family member 4, phocein

increases expression

Tacrolimus results in increased expression of MOB4 mRNA

NCBI chr 9:56,617,374...56,641,336
Ensembl chr 9:56,617,368...56,641,329

G

myeloperoxidase

multiple interactions
decreases expression

Tacrolimus inhibits the reaction [Indomethacin results in increased activity of MPO protein]
Tacrolimus results in decreased expression of MPO protein

PMID:9655420 PMID:17202747

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

mitochondrial rRNA methyltransferase 3

decreases expression

Tacrolimus results in decreased expression of MRM3 mRNA

NCBI chr10:61,095,920...61,125,421
Ensembl chr10:61,095,952...61,102,630

G

membrane spanning 4-domains A6A

increases expression

Tacrolimus results in increased expression of MS4A6C mRNA

NCBI chr 1:208,401,465...208,414,831
Ensembl chr 1:208,401,466...208,414,758

G

mesothelin

increases expression

Tacrolimus results in increased expression of MSLN mRNA

NCBI chr10:14,771,946...14,781,382
Ensembl chr10:14,771,961...14,777,643

G

MYC proto-oncogene, bHLH transcription factor

increases expression

Tacrolimus results in increased expression of MYC mRNA

PMID:21865292 PMID:23958496

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

N-acylethanolamine acid amidase

increases expression

Tacrolimus results in increased expression of NAAA mRNA

NCBI chr14:15,777,306...15,796,411
Ensembl chr14:15,777,306...15,796,410

G

NCK associated protein 1 like

increases expression

Tacrolimus results in increased expression of NCKAP1L mRNA

NCBI chr 7:134,577,470...134,622,928
Ensembl chr 7:134,577,482...134,622,934

G

natural cytotoxicity triggering receptor 3

increases expression

Tacrolimus results in increased expression of NCR3

NCBI chr20:3,637,242...3,643,748
Ensembl chr20:3,638,240...3,643,799

G

N-myc downstream regulated 1

increases expression

Tacrolimus results in increased expression of NDRG1 mRNA

NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880

G

nuclear factor of activated T-cells 3

multiple interactions

Tacrolimus inhibits the reaction [bisphenol A promotes the reaction [NFATC3 protein binds to IL4 promoter]]; Tacrolimus inhibits the reaction [nonylphenol promotes the reaction [NFATC3 protein binds to IL4 promoter]]; Tacrolimus inhibits the reaction [Thapsigargin affects the localization of and results in increased activity of NFATC3 protein]

PMID:10339586 PMID:12709020

NCBI chr19:33,960,643...34,035,150
Ensembl chr19:33,960,852...34,035,150

G

nuclear factor of activated T-cells 4

multiple interactions

Tacrolimus inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein]; Tacrolimus inhibits the reaction [Phenylephrine results in increased localization of NFATC4 protein]

NCBI chr15:29,286,998...29,314,610
Ensembl chr15:29,305,535...29,314,610

G

NFE2 like bZIP transcription factor 2

increases expression

Tacrolimus results in increased expression of NFE2L2 protein

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

multiple interactions
increases expression

Tacrolimus inhibits the reaction [Tetrachlorodibenzodioxin affects the localization of NFKB1 protein]
Tacrolimus results in increased expression of NFKB1 mRNA

PMID:18172213 PMID:18172886 PMID:23958496

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

nuclear factor kappa B subunit 2

increases expression

Tacrolimus results in increased expression of NFKB2 mRNA

NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213

G

NFKB inhibitor alpha

decreases degradation
increases phosphorylation
multiple interactions

Tacrolimus results in decreased degradation of NFKBIA protein
Tacrolimus results in increased phosphorylation of NFKBIA protein
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Tacrolimus results in increased phosphorylation of NFKBIA protein]

PMID:16181452 PMID:23958496

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NFKB inhibitor beta

multiple interactions

Tacrolimus inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of NFKBIB protein]